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Globally,	  norovirus	  is	  the	  most	  common	  cause	  of	  acute	  sporadic	  gastroenteritis	  in	  
adults	  and	  the	  second	  leading	  cause	  of	  severe	  diarrhea	  in	  children,	  after	  rotavirus.	  	  
Vaccine	  development	  against	  norovirus	  is	  currently	  underway.	  	  Successful	  
vaccination	  strategies	  against	  norovirus	  will	  require	  understanding	  the	  burden	  of	  
disease	  and	  relevant	  genotypes	  in	  target	  populations.	  However,	  due	  to	  the	  cost	  
associated	  with	  molecular	  diagnostics,	  few	  data	  are	  available	  from	  populations	  
living	  in	  low-­‐	  and	  middle-­‐income	  countries	  (LMIC).	  	  We	  conducted	  epidemiological	  
studies	  in	  two	  populations.	  	  (1)	  To	  evaluate	  the	  burden	  of	  disease,	  predominate	  
genotypes,	  and	  associated	  symptoms	  among	  adults	  living	  in	  an	  LMIC	  setting,	  we	  
conducted	  a	  nested	  case-­‐control	  study	  within	  a	  Peruvian	  military	  cohort	  from	  2004	  
through	  2011.	  	  We	  then	  used	  the	  epidemiological	  data	  from	  this	  study	  to	  evaluate	  
the	  cost-­‐effectiveness	  of	  a	  potential	  vaccine	  against	  norovirus	  in	  this	  adult	  
population.	  (2)	  We	  then	  conducted	  a	  case-­‐control	  study	  in	  the	  national	  children’s	  
hospital	  in	  Peru	  following	  the	  universal	  implementation	  of	  a	  vaccine	  against	  
rotavirus	  in	  order	  to	  determine	  the	  a)	  pathogen-­‐specific	  attributable	  risk	  among	  
children	  with	  medically-­‐attended	  gastroenteritis;	  b)	  relationship	  between	  pediatric	  
infection	  with	  specific	  pathogens	  and	  gastroenteritis	  severity;	  and	  c)	  genetic	  
diversity	  of	  circulating	  norovirus,	  sapovirus,	  and	  rotavirus.	  	  	  We	  found	  that,	  after	  
Shigella,	  norovirus	  was	  the	  leading	  cause	  of	  diarrhea	  in	  the	  adult	  Peruvian	  military	  
population,	  contributing	  to	  a	  disease	  attributable	  fraction	  (AF)	  of	  6.4%.	  	  Relative	  to	  
implementation	  in	  the	  United	  States,	  we	  calculated	  Shigella	  vaccine	  implementation	  
to	  be	  significantly	  more	  cost-­‐effective	  for	  the	  Peruvian	  military	  (CERDDL=$350	  
 
	  iv	  
versus	  $1275),	  with	  norovirus	  vaccine	  implementation	  being	  moderately	  more	  cost	  
effective	  (CERDDL=$926	  versus	  $1344).	  	  In	  the	  pediatric	  hospital	  population,	  we	  
found	  that	  the	  following	  six	  pathogens	  were	  independently	  positively	  associated	  
with	  gastroenteritis:	  norovirus	  GII	  (AF	  29.1,	  95%	  CI:	  28.0-­‐32.3);	  rotavirus	  (AF	  8.9,	  
95%	  CI:	  6.8-­‐9.7);	  	  sapovirus	  (AF	  6.3,	  95%	  CI:	  4.3-­‐7.4);	  ETEC	  St=/Lt+St+	  (AF	  2.4,	  95%	  
CI:	  0.6-­‐3.1);	  Shigella	  (AF	  2.0,	  95%	  CI:	  0.4-­‐2.2);	  and	  astrovirus	  (AF	  2.8,	  95%	  CI:	  0.0-­‐
4.0).	  	  Caliciviruses	  are	  an	  important	  cause	  of	  diarrhea	  among	  children	  with	  
medically-­‐attended	  diarrhea	  in	  Peru,	  as	  well	  as	  adults	  in	  special	  populations,	  such	  as	  
the	  military.	  Control	  strategies	  should	  consider	  multivalent	  vaccines	  that	  target	  
these	  pathogens.	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I.	  	  REVIEW:	  	  CURRENT	  CONCEPTS	  IN	  TROPICAL	  AND	  TRAVEL-­‐ASSOCIATED	  
NOROVIRUS	  GASTROENTERITIS	  	  	  
	  
INTRODUCTION	  
Globally,	  norovirus	  is	  the	  most	  common	  cause	  of	  acute	  sporadic	  gastroenteritis	  in	  
adults	  and	  the	  second	  leading	  cause	  of	  severe	  diarrhea	  in	  children,	  after	  rotavirus.	  	  
In	  countries	  with	  mature	  rotavirus	  immunization	  programs,	  norovirus	  is	  emerging	  
as	  the	  predominant	  diarrhea-­‐associated	  pathogen	  in	  young	  children	  (Pringle	  et	  al.	  
2015).	  	  This	  section	  covers	  the	  latest	  scientific	  insights	  into	  norovirus	  infections	  in	  
the	  tropics	  while	  addressing	  the	  challenges	  of	  controlling	  this	  disease	  in	  endemic	  
populations	  and	  travelers	  to	  these	  regions.	  	  	  	  	  	  	  	  	  
	  
ASSESSING	  NOROVIRUS	  DISEASE	  BURDEN	  IN	  THE	  TROPICS	  
Norovirus	  detection	  in	  symptomatic	  cases.	  	  Ahmed	  and	  colleagues	  estimated	  a	  
global	  norovirus	  prevalence	  of	  18%	  among	  acute	  gastroenteritis	  cases	  in	  a	  meta-­‐
analysis	  of	  175	  studies	  published	  between	  2008	  and	  2014	  (S.	  M.	  Ahmed	  et	  al.	  2014).	  	  
The	  pooled	  prevalences	  among	  hospitalized	  and	  community	  cases	  were	  17%	  and	  
24%,	  respectively	  (S.	  M.	  Ahmed	  et	  al.	  2014).	  	  When	  stratified	  by	  World	  Health	  
Organization	  (WHO)	  mortality	  category	  (Beaglehold	  and	  Prentice	  2003),	  norovirus	  
was	  more	  prevalent	  in	  diarrhea	  stools	  from	  low-­‐mortality	  than	  high-­‐mortality	  
developing	  settings	  (19%	  versus	  14%,	  respectively)	  (S.	  M.	  Ahmed	  et	  al.	  2014).	  	  This	  
likely	  represents	  a	  more	  diverse	  enteropathogen	  landscape	  in	  the	  context	  of	  higher	  
overall	  diarrhea	  incidence	  in	  high-­‐mortality	  settings	  (S.	  M.	  Ahmed	  et	  al.	  2014).	  	  Prior	  
to	  rotavirus	  vaccine	  implementation,	  norovirus	  was	  the	  most	  frequently	  identified	  
pathogen	  in	  ambulatory	  (Estévez	  et	  al.	  2013)	  and	  community	  (Saito	  et	  al.	  2014)	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diarrhea	  cases	  in	  certain	  low-­‐	  and	  middle-­‐income	  country	  (LMIC)	  settings.	  	  
Rotavirus	  was	  usually	  reported	  more	  frequently	  in	  hospitalized	  children	  (Estévez	  et	  
al.	  2013),	  although	  up	  to	  55%	  of	  hospital	  diarrhea	  cases	  demonstrated	  human	  
calicivirus	  (norovirus	  and/or	  sapovirus)	  infection	  when	  evaluated	  with	  both	  
immunologic	  and	  molecular	  detection	  methods	  (Parashar	  et	  al.	  2004;	  Cama	  et	  al.	  
1999).	  	  Following	  successful	  universal	  rotavirus	  vaccination	  in	  LMICs,	  norovirus	  is	  
recognized	  as	  the	  predominant	  pathogen	  in	  hospitalized	  (Bucardo	  et	  al.	  2014),	  
outpatient	  (Estévez	  et	  al.	  2013),	  and	  community	  (Becker-­‐Dreps	  et	  al.	  2014)	  diarrhea	  
cases.	  	  The	  relationship	  between	  norovirus	  infection	  and	  adult	  diarrhea	  has	  not	  
been	  previously	  evaluated	  LMIC	  military	  service	  members	  (Ballard,	  Reaves,	  et	  al.	  
2015a).	  
	  
Norovirus	  detection	  in	  asymptomatic	  individuals.	  	  The	  detection	  of	  norovirus	  in	  
stools	  from	  asymptomatic	  individuals	  complicates	  disease	  burden	  estimates.	  	  
Globally,	  the	  pooled	  asymptomatic	  prevalence	  from	  the	  20	  controlled	  studies	  in	  
Ahmed’s	  meta-­‐analysis	  was	  7%	  (S.	  M.	  Ahmed	  et	  al.	  2014).	  Fifteen	  to	  35%	  of	  
norovirus	  infections	  are	  asymptomatic,	  but	  both	  symptomatically-­‐	  and	  
asymptomatically-­‐infected	  individuals	  shed	  virus	  at	  similar	  levels	  for	  similar	  
amounts	  of	  time,	  although	  duration	  may	  vary	  by	  genotype	  and	  variant	  (Saito	  et	  al.	  
2014).	  	  Host	  genetic	  factors,	  such	  as	  the	  absence	  of	  the	  alpha-­‐1,2-­‐fucosyltransferase	  
(FUT2)	  enzyme	  in	  “secretor	  negative”	  individuals,	  appear	  to	  confer	  absolute	  
protection	  to	  infection	  to	  specific	  variants	  (Ben	  A.	  Lopman	  et	  al.	  2015).	  	  Other	  host	  
factors,	  such	  as	  histo-­‐blood	  group	  antigen	  polymorphisms,	  result	  in	  heterogeneous	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susceptibility	  to	  norovirus	  infection	  (Ben	  A.	  Lopman	  et	  al.	  2015).	  	  Following	  
infection,	  viral	  shedding	  lasts	  approximately	  20-­‐30	  days	  in	  adults	  (M.	  M.	  Levine	  and	  
Robins-­‐Browne	  2012).	  	  Excretion	  can	  be	  prolonged	  in	  children,	  the	  elderly,	  and	  
immunocompromised,	  who	  serve	  as	  reservoirs	  for	  transmission	  (Sukhrie	  et	  al.	  
2010)	  and	  may	  also	  contribute	  to	  the	  emergence	  of	  novel	  epidemic	  variants	  (Pringle	  
et	  al.	  2015).	  	  In	  Saito	  and	  colleagues’	  Peruvian	  birth	  cohort,	  norovirus	  excretion	  was	  
longer	  for	  genogroup	  (G)	  II	  (median	  34.5	  days;	  maximum	  98)	  than	  GI	  (median	  8.5	  
days;	  maximum	  49)	  (Saito	  et	  al.	  2014).	  	  Both	  symptomatic	  and	  asymptomatic	  
infections	  during	  the	  first	  year	  of	  life	  were	  associated	  with	  linear	  growth	  deficits	  
that	  persisted	  into	  the	  second	  year	  of	  life	  (Saito	  et	  al.	  2014).	  	  	  
	  
In	  the	  absence	  of	  longitudinal	  data,	  distinguishing	  symptomatic	  from	  asymptomatic	  
norovirus	  infections	  is	  difficult.	  	  Asymptomatic	  individuals	  tend	  to	  have	  higher	  RT-­‐
PCR	  cycle	  thresholds	  values	  than	  individuals	  with	  acute	  gastroenteritis,	  but	  there	  is	  
no	  clear	  viral	  load	  cutoff	  that	  corresponds	  with	  symptom	  resolution	  (Phillips	  et	  al.	  
2009).	  To	  illustrate	  the	  marked	  increase	  in	  asymptomatic	  norovirus	  prevalence	  
resulting	  in	  small	  increases	  in	  basic	  reproduction	  number,	  Lopman	  and	  colleagues	  
created	  a	  dynamic	  norovirus	  transmission	  model	  of	  norovirus	  infection,	  immunity,	  
and	  disease	  (B.	  Lopman	  et	  al.	  2014).	  In	  this	  model,	  the	  case:	  control	  prevalence	  ratio	  
was	  high	  in	  developed	  settings	  and	  decreased	  dramatically	  in	  a	  high-­‐exposure	  
scenario	  with	  the	  same	  disease	  incidence	  (B.	  Lopman	  et	  al.	  2014).	  	  This	  could	  
explain	  why	  the	  Global	  Enteric	  Multi-­‐Center	  Study	  (GEMS),	  a	  case-­‐control	  analysis	  of	  
diarrhea	  in	  the	  tropics,	  noted	  similar	  frequencies	  of	  norovirus	  in	  case	  and	  control	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stools,	  ultimately	  dermined	  that	  norovirus	  contributed	  minimally	  to	  moderate-­‐to-­‐
severe	  diarrheal	  disease	  (Kotloff	  et	  al.	  2013).	  	  In	  contrast,	  longitudinal	  studies	  that	  
more	  clearly	  distinguish	  symptomatic	  and	  asymptomatic	  infections	  demonstrate	  
higher	  burdens	  of	  norovirus-­‐associated	  diarrhea	  in	  similar	  developing	  settings	  
(Saito	  et	  al.	  2014;	  B.	  Lopman	  and	  Kang	  2014).	  	  In	  their	  Peruvian	  birth	  cohort,	  Saito	  
and	  colleagues	  calculated	  a	  norovirus	  attributable	  diarrheal	  disease	  fraction	  of	  7.8%	  
in	  the	  first	  and	  23.1%	  in	  the	  second	  year	  of	  life	  (Saito	  et	  al.	  2014).	  	  
	  
Defining	  norovirus	  disease	  and	  severity.	  The	  lack	  of	  standard	  norovirus	  case	  
definitions	  and	  clinical	  severity	  measures	  complicate	  disease	  burden	  estimation	  and	  
comparative	  intervention	  evaluations	  in	  tropical	  settings.	  	  Historically	  dubbed	  
“winter	  vomiting	  disease,”	  norovirus	  often	  causes	  emesis	  in	  the	  absence	  of	  diarrhea.	  	  
As	  a	  result,	  diarrhea-­‐based	  gastroenteritis	  case	  definitions	  likely	  underestimate	  
disease	  burden	  by	  excluding	  vomiting-­‐only	  disease.	  	  Of	  the	  175	  studies	  included	  in	  
Ahmed	  and	  colleagues’	  meta-­‐analysis	  of	  norovirus	  gastroenteritis,	  143	  (82%)	  either	  
did	  not	  provide	  a	  case	  definition	  for	  acute	  gastroenteritis	  or	  excluded	  vomiting-­‐only	  
disease.	  	  Clinical	  severity	  measures	  are	  most	  commonly	  based	  on	  the	  20-­‐point	  
Vesikari	  scale,	  which	  dichotomizes	  gastroenteritis	  into	  “mild”	  (<11)	  or	  “severe”	  
disease	  (Vesikari,	  Giaquinto,	  and	  Huppertz	  2006;	  Ruuska	  and	  Vesikari	  1990).	  	  Other	  
measures	  of	  disease	  severity	  include	  the	  24-­‐point	  Clark	  scale	  (H.	  F.	  Clark	  et	  al.	  
1988),	  modified	  Vesikari	  scales	  (Saito	  et	  al.	  2014),	  the	  World	  Health	  Organization	  
scale	  (“The	  Treatment	  of	  Diarrhea.	  A	  Manual	  for	  Physicians	  and	  Other	  Senior	  Health	  
Workers.	  Fourth	  Revision,	  2005”	  2005),	  and	  severity	  scores	  based	  on	  signs	  and	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symptoms	  (Monica	  et	  al.	  2007;	  El	  Qazoui	  et	  al.	  2014;	  Abugalia	  et	  al.	  2011;	  Chhabra	  
et	  al.	  2009;	  Farkas	  et	  al.	  2000;	  Gutiérrez-­‐Escolano	  et	  al.	  2010),	  reported	  symptoms	  
(Yang	  et	  al.	  2010;	  Räsänen	  et	  al.	  2011;	  Sdiri-­‐Loulizi	  et	  al.	  2008;	  Flores	  et	  al.	  
2011)(28	  Yang,	  29	  Rasanen,	  30	  Sdiri-­‐Loulizi,	  31	  Flores),	  length	  of	  hospitalization	  
(Räsänen	  et	  al.	  2011;	  So	  et	  al.	  2013)	  and	  impact	  on	  daily	  activities	  (Lalani	  et	  al.	  
2015).	  Different	  gastroenteritis	  case	  and	  severity	  definitions	  can	  bias	  results	  against	  
specific	  pathogens.	  	  For	  example,	  defining	  “moderate-­‐to-­‐severe”	  diarrhea	  as	  the	  
presence	  of	  sunken	  eyes,	  loss	  of	  skin	  turgor,	  intravenous	  fluid	  prescription,	  
dysentery,	  or	  hospital	  admission,	  GEMS	  reported	  that	  norovirus	  contributed	  
minimally	  to	  moderate-­‐to-­‐severe	  disease	  (Kotloff	  et	  al.	  2013).	  	  In	  contrast,	  O’Ryan	  
and	  colleagues’	  hospital-­‐based	  study	  of	  diarrheal	  disease	  in	  Chile	  reported	  that	  
norovirus	  was	  a	  leading	  cause	  of	  moderate-­‐to-­‐severe	  disease,	  as	  defined	  by	  a	  
Vesikari	  score	  greater	  than	  6	  (of	  20	  possible	  points)	  (Ruuska	  and	  Vesikari	  1990;	  
O’Ryan	  et	  al.	  2010).	  	  Using	  uniform	  case	  definitions	  and	  severity	  measures	  for	  
norovirus	  vaccine	  efficacy	  studies	  will	  allow	  direct	  comparison	  of	  results,	  avoiding	  
the	  possibility	  that	  different	  results	  might	  be	  attributable	  to	  the	  use	  of	  differing	  
scales,	  as	  was	  the	  case	  when	  Rotateq®	  and	  Rotarix®	  were	  evaluated	  using	  the	  Clark	  
and	  Vesikari	  scales,	  respectively	  (Givon-­‐Lavi,	  Greenberg,	  and	  Dagan	  2008).	  	  	  
	  
Malnutrition	  and	  norovirus	  infection.	  	  Undernutrition	  affects	  one	  in	  five	  children	  
in	  the	  tropics	  and	  has	  been	  associated	  with	  half	  of	  deaths	  in	  children	  younger	  than	  
five	  years	  worldwide	  (Bryce	  et	  al.	  2017).	  	  Poor	  nutrition	  weakens	  host	  immune	  
responses	  and	  alters	  the	  gut	  microbiota,	  both	  of	  which	  can	  worsen	  the	  clinical	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course	  of	  diarrheal	  disease	  (Hickman	  et	  al.	  2014).	  After	  infecting	  well-­‐nourished	  and	  
protein	  energy	  deficient	  mice	  with	  murine	  norovirus,	  Hickman	  and	  colleagues	  found	  
that	  malnourished	  mice	  demonstrated	  more	  weight	  loss,	  reduced	  antibody	  
responses,	  loss	  of	  protective	  immunity,	  and	  enhanced	  viral	  evolution	  (Hickman	  et	  al.	  
2014).	  	  Although	  the	  well-­‐nourished	  mice	  fared	  better	  in	  terms	  of	  disease	  severity,	  
norovirus	  infection	  resulted	  in	  a	  gut	  microbial	  environment	  similar	  to	  that	  of	  
malnourished	  mice	  (Hickman	  et	  al.	  2014).	  	  Human	  studies	  are	  currently	  being	  
conducted	  by	  the	  Interactions	  of	  Malnutrition	  &	  Enteric	  Infections:	  Consequences	  
for	  Child	  Health	  and	  Development	  (MAL-­‐ED)	  group,	  but	  results	  are	  pending	  (MAL-­‐
ED	  Network	  Investigators	  et	  al.	  2014;	  Richard	  et	  al.	  2014;	  Houpt	  et	  al.	  2014;	  J.	  A.	  
Platts-­‐Mills	  et	  al.	  2014;	  T.	  Ahmed	  et	  al.	  2014;	  Lima	  et	  al.	  2014;	  John	  et	  al.	  2014;	  
Shrestha	  et	  al.	  2014;	  Turab	  et	  al.	  2014;	  P.	  P.	  Yori	  et	  al.	  2014;	  Bessong	  et	  al.	  2014;	  
Mduma	  et	  al.	  2014).	  	  Particularly	  relevant	  to	  assessing	  tropical	  norovirus	  infections	  
are	  investigations	  that	  assess	  the	  role	  of	  the	  gut	  microbiota	  in	  nutritional	  status	  
(Lang	  2015),	  immune	  markers	  and	  vaccine	  failure	  in	  undernourished	  populations	  
(Hoest	  et	  al.	  2014;	  Keusch	  et	  al.	  2014),	  tropical	  enteropathy	  and	  gut	  function	  (Hoest	  
et	  al.	  2014;	  Kosek	  et	  al.	  2014;	  Denno	  et	  al.	  2014),	  and	  the	  long-­‐term	  impact	  of	  these	  
factors	  on	  child	  development	  (MAL-­‐ED	  Network	  Investigators	  et	  al.	  2014;	  Murray-­‐
Kolb	  et	  al.	  2014).	  	  
	  
Norovirus	  coinfections.	  	  Individuals	  living	  in	  tropical	  settings	  often	  have	  intense	  
exposure	  to	  enteric	  pathogens,	  and	  detection	  of	  more	  than	  one	  pathogen,	  
particularly	  helminths,	  in	  stool	  samples	  is	  common.	  	  Helminth	  coinfections	  impair	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viral	  immunity	  via	  an	  innate	  immunomodulation	  pathway.	  	  In	  this	  pathway,	  
helminth-­‐activated	  TH2	  cells	  release	  interleukin	  (IL)-­‐4	  and	  IL-­‐13,	  which	  ligate	  IL-­‐4	  
receptors	  on	  M2	  macrophages	  (Osborne	  et	  al.	  2014;	  Maizels	  and	  Gause	  2014).	  	  This	  
inhibits	  the	  production	  of	  virus-­‐specific	  T-­‐cells	  and	  greatly	  increases	  viral	  
replication	  in	  macrophages	  (Maizels	  and	  Gause	  2014).	  	  Helminth	  infections	  are	  also	  
associated	  with	  changes	  in	  the	  gut	  microbiota	  (Walk	  et	  al.	  2010;	  Rausch	  et	  al.	  2013),	  
although	  the	  extent	  to	  which	  these	  changes	  affect	  host	  responses	  to	  viruses	  and	  
other	  enteropathogens	  is	  not	  clear.	  	  The	  type	  2	  immune	  response	  stimulated	  by	  
helminth	  infection	  is	  also	  associated	  with	  enhanced	  tissue	  repair	  and	  reduced	  
inflammation	  (Gause,	  Wynn,	  and	  Allen	  2013),	  which	  could	  mitigate	  the	  severity	  of	  
disease	  in	  coinfected	  individuals.	  	  
	  
The	  molecular	  and	  cellular	  interactions	  between	  enteropathogens	  are	  important	  to	  
consider	  when	  evaluating	  norovirus	  disease	  burden	  and	  pathogen-­‐specific	  
interventions	  (Kjetland	  et	  al.	  2014).	  However,	  currently	  used	  qualitative	  pathogen	  
detection	  (J.	  Liu	  et	  al.	  2013;	  James	  A.	  Platts-­‐Mills	  et	  al.	  2014)	  and	  regression-­‐based	  
coinfection	  adjustment	  (Kotloff	  et	  al.	  2013)	  methods	  are	  imperfect	  in	  the	  setting	  of	  
asymptomatic	  infection,	  post-­‐infectious	  shedding	  (Rao	  et	  al.	  2001),	  and	  varying	  
durations	  of	  immunity	  (Simmons	  et	  al.	  2013).	  	  Probabilistic	  analytical	  methods	  that	  
give	  weight	  to	  first	  infections	  and	  account	  for	  pathogen	  prevalance	  prior	  to	  
symptom	  onset	  may	  present	  a	  clearer	  picture	  of	  pathogen-­‐specific	  disease	  burdens	  
in	  tropical	  settings	  where	  polymicrobial	  infections	  are	  detected	  frequently	  




NOROVIRUS	  IN	  TRAVELERS	  TO	  THE	  TROPICS	  
Up	  to	  100	  million	  people	  from	  high-­‐income	  countries	  travel	  to	  the	  tropics	  each	  year,	  
and	  40-­‐60%	  of	  them	  develop	  diarrhea	  (Harvey	  et	  al.	  2013;	  de	  la	  Cabada	  Bauche	  and	  
Dupont	  2011).	  	  Norovirus	  is	  the	  second	  leading	  cause	  of	  travelers’	  diarrhea	  after	  
Enteropathogenic	  Escherichia	  coli	  (ETEC)	  (Youmans	  et	  al.	  2015).	  	  A	  systematic	  
review	  of	  51	  published	  studies	  of	  travelers’	  diarrhea	  reported	  a	  pooled	  norovirus	  
case	  stool	  prevalence	  of	  6.6%,	  with	  higher	  norovirus	  prevalence	  in	  stools	  from	  
travelers	  to	  Latin	  America	  (16.9%)	  and	  Africa	  (12.8%)	  than	  travelers	  to	  Asia	  (3.2%)	  
(Beckmann	  et	  al.	  2014).	  	  Norovirus	  has	  been	  associated	  with	  diarrhea	  in	  both	  
children	  and	  adults	  returning	  from	  tropical	  settings	  (Beckmann	  et	  al.	  2014),	  and	  
norovirus	  coinfections	  with	  other	  pathogens,	  particularly	  ETEC,	  are	  common,	  
(Gonzaga	  et	  al.	  2011;	  Paschke	  et	  al.	  2011).	  	  Travelers’	  diarrhea	  is	  associated	  with	  
alterations	  in	  the	  gut	  microbiota	  that	  appear	  similar,	  regardless	  of	  the	  infecting	  
enteropathogen	  (Youmans	  et	  al.	  2015).	  	  	  
	  
Norovirus	  afloat.	  	  Norovirus	  has	  a	  very	  low	  infectious	  dose	  (Teunis	  et	  al.	  2008;	  
Thebault	  et	  al.	  2013;	  Kirby,	  Teunis,	  and	  Moe	  2015;	  Atmar	  et	  al.	  2014)	  and	  is	  
extremely	  hard	  to	  eliminate	  from	  the	  environment	  (Parashar	  et	  al.	  2004),	  making	  
contamination	  of	  ships	  common.	  	  The	  US	  Centers	  for	  Disease	  Control	  and	  
Prevention’s	  Vessel	  Sanitation	  Program	  assists	  to	  prevent	  outbreaks	  on	  ships	  with	  
foreign	  itineraries,	  where	  the	  impact	  of	  norovirus	  has	  been	  well	  documented	  
(Beaumier	  2007).	  	  During	  the	  1990s,	  the	  implementation	  of	  sanitation	  measures	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resulted	  in	  the	  reduction	  of	  norovirus	  outbreaks	  from	  6.3	  to	  3.7	  per	  1,000	  ship-­‐
weeks	  (Cramer,	  Gu,	  and	  Durbin	  2003).	  	  In	  US	  military	  populations	  afloat,	  
gastroenteritis	  outbreaks	  have	  been	  reported	  at	  nearly	  ten	  times	  the	  rate	  of	  
vacation	  cruise	  ships,	  with	  an	  overall	  incidence	  of	  33.2	  outbreaks	  per	  1,000	  ship-­‐
weeks	  among	  44	  Navy	  ships	  deployed	  to	  the	  Middle	  East	  during	  a	  12-­‐month	  
analysis	  period	  (Riddle	  et	  al.	  2006).	  	  It	  is	  assumed	  that	  norovirus	  contributed	  
significantly	  to	  these	  outbreaks	  since	  a	  concurrent	  surveillance	  study	  identified	  
norovirus	  in	  at	  least	  one	  of	  the	  eleven	  outbreaks	  included	  in	  this	  study,	  and	  in	  4	  of	  4	  
Navy	  ships	  which	  submitted	  outbreak	  stool	  specimens	  for	  testing	  as	  part	  of	  a	  
separate	  surveillance	  report	  (Riddle	  et	  al.	  2006)(79	  Riddle).	  	  Attack	  rates	  were	  
similar	  on	  large	  and	  small	  military	  ships	  (3.3%	  overall),	  but	  larger	  ships	  had	  more	  
frequent	  outbreaks	  than	  smaller	  ships	  (66	  versus	  26	  per	  1,000	  ship	  weeks,	  
respectively)	  (Riddle	  et	  al.	  2006).	  Smaller	  ships	  had	  increased	  outbreak	  durations,	  
possibly	  because	  less	  intense	  transmission	  resulted	  in	  slower	  saturation	  of	  the	  
susceptible	  population	  relative	  to	  the	  more	  crowded	  big	  ships	  (Riddle	  et	  al.	  2006).	  	  
Unlike	  international	  cruise	  ships,	  which	  demonstrate	  a	  winter-­‐spring	  
predominance,	  US	  Navy	  shipboard	  outbreaks	  occurred	  throughout	  the	  year	  (Riddle	  
et	  al.	  2006).	  	  	  	  	  	  	  	  
	  
Norovirus	  in	  deployed	  troops	  ashore.	  	  Norovirus	  outbreaks	  among	  ground	  troops	  
in	  deployed	  settings	  are	  also	  common.	  	  Among	  20,320	  deployed	  US	  service	  members	  
presenting	  with	  acute	  gastroenteritis	  from	  2005-­‐12,	  60%	  of	  cases	  were	  associated	  
with	  viral	  pathogens,	  and	  norovirus	  detection	  increased	  steadily	  from	  2006	  to	  2012	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(“Gastrointestinal	  Infections,	  Active	  Component,	  U.S.	  Armed	  Forces,	  2002-­‐2012.”	  
2013).	  	  Still	  another	  25,938	  cases	  from	  this	  period	  were	  documented	  as	  “non-­‐
specific	  diarrhea,”	  although	  norovirus	  likely	  contributed	  significantly	  
(“Gastrointestinal	  Infections,	  Active	  Component,	  U.S.	  Armed	  Forces,	  2002-­‐2012.”	  
2013).	  During	  Operations	  Desert	  Shield	  and	  Desert	  storm,	  numerous	  norovirus	  
outbreaks	  occurred	  in	  service	  members	  (Hyams	  et	  al.	  1991;	  McCarthy,	  Estes,	  and	  
Hyams	  2000;	  DeMaio	  et	  al.	  1993).	  	  Norovirus	  outbreaks	  also	  clustered	  at	  the	  
beginning	  of	  the	  conflicts	  in	  Iraq	  and	  Afghanistan	  (Ahmad	  2002;	  M	  S	  Bailey	  et	  al.	  
2008;	  Centers	  for	  Disease	  Control	  and	  Prevention	  (CDC)	  2002;	  Matson	  2005).	  	  One	  
norovirus	  outbreak	  resulted	  in	  the	  evacuation	  of	  11	  British	  troops	  from	  Afghanistan,	  
including	  one	  individual	  with	  disseminated	  intravascular	  coagulation	  and	  two	  
requiring	  ventilator	  support	  (Centers	  for	  Disease	  Control	  and	  Prevention	  (CDC)	  
2002).	  	  This	  outbreak	  highlighted	  the	  potential	  for	  norovirus	  to	  cause	  severe	  disease	  
in	  individuals	  under	  extreme	  environmental	  stress	  (Centers	  for	  Disease	  Control	  and	  
Prevention	  (CDC)	  2002).	  	  In	  another	  norovirus	  outbreak	  in	  Iraq,	  975	  of	  1,340	  
affected	  British	  troops	  were	  admitted	  to	  a	  field	  hospital,	  where	  significant	  
transmission	  to	  medical	  staff	  occurred,	  resulting	  in	  hospital	  closure	  (M	  S	  Bailey	  et	  al.	  
2008;	  Delacour,	  Dubrous,	  and	  Koeck	  2010;	  Mark	  S	  Bailey	  et	  al.	  2005).	  	  
	  
Environmental	  and	  behavioral	  risk	  factors.	  	  The	  environmental	  and	  behavioral	  
risk	  factors	  associated	  with	  norovirus	  infection	  have	  common	  themes	  across	  
populations.	  	  In	  cruise	  ship	  patrons,	  cabin	  mate	  sick	  with	  diarrhea	  or	  vomiting	  and	  
using	  vomitus-­‐contaminated	  bathrooms	  are	  associated	  with	  infections	  (Chimonas	  et	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al.	  2008).	  	  	  Among	  infected	  foodhandlers,	  the	  long	  shedding	  period	  of	  norovirus,	  
particularly	  in	  asymptomatically	  infected	  or	  post-­‐symptomatic	  individuals,	  
contributes	  to	  population	  transmission	  (M.-­‐A.	  Sanchez	  et	  al.	  2017).	  	  In	  military	  
settings,	  where	  all	  population	  members	  eat	  at	  the	  same	  dining	  facility,	  norovirus	  can	  
be	  introduced	  by	  multiple	  food	  service	  workers	  during	  outbreaks	  and	  then	  further	  
spread	  among	  personnel	  (Chapman	  et	  al.	  2011).	  	  Additional	  risks	  include	  cleaning	  
bathrooms	  and	  exposure	  to	  norovirus-­‐contaminated	  water	  sources	  while	  
completing	  obstacle	  courses	  or	  swimming,	  and	  brushing	  teeth	  or	  consuming	  water	  
that	  did	  not	  come	  from	  a	  water	  trailer	  (Chapman	  et	  al.	  2011).	  	  In	  children	  living	  in	  
developing	  settings,	  younger	  age	  and	  having	  animals	  in	  the	  household	  appears	  to	  
increase	  the	  risk	  of	  norovirus	  infection	  (BECKER-­‐DREPS	  et	  al.	  2017).	  	  While	  
norovirus	  is	  traditionally	  called	  the	  “winter	  vomiting	  disease,”	  this	  seasonality	  does	  
not	  appear	  to	  be	  consistent	  across	  geographic	  locations.	  	  In	  Nicaragua,	  Cameroon,	  
and	  elsewhere,	  the	  rainy	  season	  has	  been	  associated	  with	  increased	  norovirus	  
incidence	  among	  children	  (BECKER-­‐DREPS	  et	  al.	  2017;	  AYUKEKBONG	  et	  al.	  2014),	  
while	  in	  Peru	  and	  other	  tropical	  countries,	  norovirus	  incidence	  increases	  during	  the	  
summer	  months	  (Saito	  et	  al.	  2014).	  	  It	  is	  not	  clear	  whether	  the	  “seasonality”	  of	  
norovirus	  is	  due	  to	  the	  effect	  of	  environmental	  factors,	  such	  as	  temperature,	  
humidity,	  and	  rainfall,	  on	  the	  virus	  itself,	  as	  suggested	  by	  some	  authors	  (Shamkhali	  
Chenar	  and	  Deng	  2016).	  	  Alternately,	  seasonality	  could	  be	  a	  result	  of	  human	  
behaviors	  that	  are	  linked	  to	  certain	  seasons,	  such	  as	  the	  start	  of	  the	  school	  year	  




NOROVIRUS	  VACCINES	  IN	  THE	  TROPICS	  
Recent	  reviews	  by	  Vesikari	  and	  colleagues	  (Vesikari	  and	  Blazevic	  2015)	  and	  
Debbink	  and	  colleagues	  (Debbink,	  Lindesmith,	  and	  Baric	  2014)	  detail	  current	  
vaccine	  development	  strategies.	  	  Briefly,	  LigoCyte	  used	  a	  baculovirus-­‐insect	  cell	  
system	  to	  develop	  the	  first	  virus	  like	  particle	  (VLP)	  vaccine	  against	  norovirus	  GI.1	  
(El‐Kamary	  et	  al.	  2010).	  	  Their	  monophosphoryl	  lipid	  A	  (MPL)	  and	  chitosan-­‐
adjuvanted	  intranasal	  vaccine	  produced	  a	  moderate	  level	  of	  protection	  against	  the	  
homologous	  virus	  in	  subsequent	  challenge	  studies	  (El‐Kamary	  et	  al.	  2010;	  Atmar	  
et	  al.	  2011).	  	  This	  proof	  of	  principle	  vaccine	  was	  followed	  by	  an	  MPL-­‐adjuvanted	  
bivalent	  GI.1/GII.4	  VLP	  vaccine	  candidate,	  delivered	  intramuscularly	  (Treanor	  et	  al.	  
2014).	  	  The	  corresponding	  challenge	  study	  was	  performed	  with	  a	  heterologous	  GII.4	  
virus,	  a	  better	  representation	  of	  natural	  infection	  than	  challenge	  with	  a	  virus	  
homologous	  to	  the	  vaccine	  VLP	  (Bernstein	  et	  al.	  2015).	  	  This	  vaccine	  provided	  100%	  
protection	  against	  severe	  vomiting	  and	  severe	  diarrhea,	  but	  was	  not	  protective	  
against	  infection,	  and	  only	  partially	  protective	  against	  symptoms	  of	  any	  severity.	  	  
Based	  on	  a	  Vesikari	  scale,	  the	  vaccine	  reduced	  diarrhea	  severity	  significantly,	  from	  
7.3	  in	  the	  placebo	  group	  to	  4.5	  in	  the	  vaccine	  group	  (Bernstein	  et	  al.	  2015).	  	  Other	  
candidate	  vaccines	  in	  development	  include	  a	  “trivalent”	  vaccine	  containing	  a	  
rotavirus	  VP6	  protein	  and	  norovirus	  GI.3	  and	  GII.4	  VLPs	  (Blazevic	  et	  al.	  2011;	  
Tamminen	  et	  al.	  2013);	  an	  intranasal	  dry-­‐powder	  vaccine	  (Velasquez	  et	  al.	  2011);	  
an	  Escherichia	  coli-­‐produced	  P	  particle	  vaccine	  (Fang	  et	  al.	  2013);	  and	  a	  combined	  
norovirus	  P	  particle-­‐rotavirus	  VP8	  antigen	  vaccine	  (Tan	  et	  al.	  2011).	  	  Multivalent	  
alpha-­‐virus	  replicon	  particle	  platforms	  for	  VLP	  formation	  (LoBue	  et	  al.	  2006);	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polyvalent	  norovirus	  P	  domain	  glutathione	  S-­‐transferase	  complexes	  (Wang	  et	  al.	  
2013);	  and	  edible	  vaccine	  delivery	  mechanisms	  (Tacket	  et	  al.	  2003)	  are	  also	  being	  
explored.	  	  Significant	  work	  remains	  to	  enhance	  the	  efficacy	  of	  norovirus	  vaccines	  
against	  genetically	  diverse	  norovirus	  variants,	  lengthen	  the	  duration	  of	  vaccine-­‐
induced	  immunity,	  lower	  vaccination	  costs,	  determine	  the	  acceptability	  of	  an	  
adjuvant,	  and	  optimize	  dosing	  and	  delivery.	  	  
	  
Vaccine	  efficacy	  considerations	  in	  the	  tropics.	  To	  date,	  norovirus	  vaccine	  trials	  
have	  occurred	  in	  well-­‐nourished	  adults	  from	  high-­‐income	  countries.	  	  However,	  
vaccine	  underperformance	  is	  characteristic	  of	  developing	  settings	  (von	  Bubnoff	  
2011;	  Qadri	  et	  al.	  2013;	  Benjamin	  A.	  Lopman	  et	  al.	  2012),	  where	  diarrhea	  is	  
common,	  the	  prevalence	  of	  undernutrition	  is	  high,	  and	  the	  duration	  of	  breastfeeding	  
suboptimal	  (Haque	  et	  al.	  2014).	  	  Recent	  mouse	  model	  studies	  demonstrated	  that	  
malnourished	  mice	  infected	  with	  murine	  norovirus	  develop	  fairly	  normal	  serum	  
antiviral	  IgG	  responses,	  but	  have	  significantly	  reduced	  mucosal	  IgA	  responses	  that	  
correspond	  with	  a	  lack	  of	  protective	  immunity	  (Hickman	  et	  al.	  2014).	  	  Parenteral	  
vaccine	  administration	  could	  potentially	  overcome	  the	  apparent	  intestinal	  barrier	  to	  
immunization	  in	  undernourished	  populations.	  	  Promoting	  exclusive	  breastfeeding	  
and	  improving	  nutrition	  may	  also	  improve	  oral	  vaccine	  performance	  in	  developing	  
settings	  (Haque	  et	  al.	  2014).	  	  Given	  that	  70%	  of	  pediatric	  norovirus	  infections	  occur	  
between	  6	  and	  24	  months	  of	  age	  worldwide,	  and	  60%	  occur	  before	  12	  months	  of	  
age	  in	  high-­‐mortality	  developing	  settings,	  a	  pediatric	  norovirus	  vaccine	  would	  have	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to	  be	  delivered	  before	  6	  months	  of	  age	  to	  prevent	  the	  majority	  of	  childhood	  
infections	  (Shioda	  et	  al.	  2015).	  	  	  
	  
Vaccine	  cost-­‐effectiveness	  in	  the	  tropics.	  	  Using	  the	  data	  collected	  for	  the	  third	  
paper	  in	  this	  dissertation,	  we	  worked	  with	  Mirelman	  to	  develop	  a	  model	  to	  evaluate	  
norovirus	  vaccine	  cost-­‐effectiveness	  in	  LMIC	  populations	  (Mirelman	  et	  al.	  2015b).	  	  
When	  applied	  to	  a	  hypothetical	  Peruvian	  birth	  cohort,	  this	  model	  found	  that	  
norovirus	  vaccination	  could	  offer	  economic	  value	  under	  the	  right	  conditions	  by	  
averting	  poor	  health	  outcomes	  and	  substantial	  healthcare	  utilization	  costs	  
(Mirelman	  et	  al.	  2015b).	  	  Assuming	  a	  two-­‐dose	  vaccination	  cost	  of	  $26.44	  per	  
individual	  vaccinated;	  85%	  vaccine	  coverage;	  the	  47%	  reported	  vaccine	  efficacy	  in	  
Atmar	  and	  colleagues’	  vaccine	  trial;	  and	  peri-­‐urban	  diarrhea	  incidence	  rates	  
reported	  by	  Saito	  and	  colleagues,	  the	  vaccine	  cost-­‐effectiveness	  was	  $19.86	  per	  
diarrhea	  case	  averted;	  $68.23	  per	  outpatient	  visit	  averted,	  and	  $21,415.95	  per	  
disability	  adjusted	  life	  year	  (DALY)	  averted	  (Mirelman	  et	  al.	  2015b).	  	  Using	  higher	  
norovirus	  incidence	  rates	  from	  a	  less	  developed	  rural	  setting,	  vaccine	  cost-­‐
effectiveness	  improved	  to	  $9.20	  per	  diarrhea	  case	  averted;	  $32.29	  per	  outpatient	  
visit	  averted;	  and	  $10,135	  per	  DALY	  averted	  (Mirelman	  et	  al.	  2015b).	  	  This	  model	  
did	  not	  include	  the	  indirect	  costs	  of	  norovirus	  infection	  or	  the	  out-­‐of-­‐pocket	  direct	  
costs	  for	  self-­‐treatment	  and	  home	  care,	  which	  are	  expected	  to	  be	  significant	  and	  
would	  further	  augment	  the	  economic	  value	  of	  norovirus	  vaccination	  (Rapoport	  et	  al.	  
2014).	  	  Likewise,	  it	  did	  not	  consider	  the	  relationship	  between	  diarrhea	  and	  
malnutrition,	  the	  prevention	  of	  which	  would	  result	  in	  additional	  health,	  social,	  and	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economic	  benefits.	  	  The	  impact	  of	  reduced	  norovirus	  transmission	  to	  older	  children	  
and	  adults	  was	  not	  included	  in	  the	  model,	  but	  could	  be	  significant	  since	  young	  
children	  play	  a	  key	  role	  in	  transmitting	  norovirus	  to	  all	  age	  groups	  (Simmons	  et	  al.	  
2013).	  	  
	  
Tallant	  and	  colleagues’	  recently	  published	  a	  new	  model	  of	  diarrhea	  vaccine	  cost-­‐
effectiveness	  for	  deploying	  US	  military	  personnel.	  	  Using	  a	  diarrhea-­‐based	  definition	  
of	  norovirus	  disease,	  they	  calculated	  a	  norovirus	  vaccine	  cost-­‐effectiveness	  of	  
$1,344	  per	  duty	  day	  lost	  averted	  (Tallant	  et	  al.	  2014a).	  	  This	  model	  assumed	  a	  two-­‐
dose	  vaccination	  cost	  of	  $60.14	  per	  individual	  vaccinated;	  75%	  vaccine	  coverage;	  
80%	  vaccine	  effectiveness,	  reflecting	  the	  minimally	  acceptable	  military	  vaccine	  
profile,	  rather	  than	  the	  efficacy	  of	  vaccines	  currently	  under	  development	  (Riddle	  
and	  Tribble	  2008;	  Riddle	  et	  al.	  2008);	  and	  a	  duration	  of	  immunity	  of	  3.5	  months,	  
which	  is	  twice	  the	  average	  duration	  of	  US	  military	  deployments	  (Tallant	  et	  al.	  
2014a).	  	  The	  estimated	  cost	  per	  duty	  day	  lost	  averted	  for	  military	  vaccines	  against	  
Campylobacter	  sp.,	  ETEC,	  and	  Shigella	  sp.,	  were	  $800,	  $776,	  and	  $1,275,	  respectively	  
(Tallant	  et	  al.	  2014a).	  	  When	  the	  norovirus	  disease	  definition	  was	  modified	  to	  
include	  vomiting,	  the	  norovirus	  vaccine	  cost	  per	  duty	  day	  lost	  averted	  decreased	  to	  
$572,	  making	  it	  the	  most	  cost-­‐effective	  of	  the	  diarrhea	  vaccines	  evaluated	  (Tallant	  et	  
al.	  2014a).	  	  As	  a	  reference,	  deployment	  operational	  costs	  per	  troop	  were	  an	  
estimated	  $935	  per	  day,	  so	  a	  norovirus	  vaccine	  with	  these	  characteristics	  would	  be	  
considered	  cost-­‐effective	  for	  deploying	  US	  military	  personnel	  (or	  cost-­‐saving,	  if	  




Besides	  young	  children	  and	  travelers	  (Jennings,	  Tilley,	  Ballard,	  Villanueva,	  Costa,	  
Lopez,	  Steinberg,	  Giannina	  Luna,	  et	  al.	  2017),	  including	  military	  service	  members	  
from	  high-­‐income	  countries	  deployed	  to	  tropical	  regions,	  other	  tropical	  and	  travel-­‐
associated	  populations	  that	  might	  benefit	  from	  norovirus	  vaccination	  include	  the	  
elderly	  (Kambhampati,	  Koopmans,	  and	  Lopman	  2015),	  hospitalized	  patients	  
(Kambhampati,	  Koopmans,	  and	  Lopman	  2015),	  individuals	  with	  immune	  
compromise,	  school-­‐aged	  children,	  developing	  country	  military	  personnel	  (Ballard,	  
Saito,	  et	  al.	  2015a),	  healthcare	  workers	  (Kambhampati,	  Koopmans,	  and	  Lopman	  
2015),	  food	  handlers,	  food	  processing	  facility	  workers,	  farm	  workers,	  and	  travel	  
industry	  workers	  (Pringle	  et	  al.	  2015).	  	  The	  key	  challenge	  of	  evaluating	  norovirus	  
vaccine	  cost-­‐effectiveness	  in	  these	  populations	  is	  the	  lack	  of	  norovirus	  disease	  
burden	  data,	  in	  addition	  to	  uncertainty	  about	  the	  price,	  dosing,	  and	  effectiveness	  of	  
candidate	  vaccines.	  	  To	  aid	  economic	  evaluations	  in	  LMICs,	  norovirus-­‐specific	  
models	  should	  be	  incorporated	  into	  existing	  cost-­‐effectiveness	  analysis	  tools	  
(Jauregui	  et	  al.	  2015).	  	  	  	  	  	  
	  
CONCLUSIONS	  	  
In	  conclusion,	  noroviruses	  are	  well	  recognized	  as	  the	  most	  common	  cause	  of	  acute	  
gastroenteritis	  in	  all	  age	  groups,	  and	  they	  are	  becoming	  the	  predominant	  pathogen	  
associated	  with	  pediatric	  diarrhea	  in	  the	  tropics	  in	  the	  wake	  of	  the	  global	  rotavirus	  
vaccine	  rollout.	  	  In	  order	  to	  appropriately	  assess	  disease	  burden	  and	  plan	  health	  
interventions	  for	  populations	  in	  developing	  settings,	  we	  will	  need	  to	  refine	  our	  case	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definitions,	  severity	  measures,	  and	  intervention	  assessment	  tools.	  	  We	  will	  also	  need	  
to	  better	  elucidate	  the	  complex	  relationship	  between	  diarrhea,	  malnutrition,	  gut	  
microbiota,	  environmental	  enteropathy,	  enteric	  co-­‐infections,	  and	  the	  immune	  
system.	  	  Multivalent	  diarrhea	  vaccines	  will	  likely	  be	  more	  cost	  effective	  if	  they	  are	  
effective	  against	  rotavirus,	  norovirus,	  and	  other	  enteropathogens,	  such	  as	  sapovirus	  
(Oka	  et	  al.	  2015),	  which	  contribute	  significantly	  to	  diarrheal	  disease.	  	  Further,	  as	  
climate	  change	  increases	  the	  incidence	  of	  diarrhea	  disease	  in	  the	  tropics,	  we	  will	  
need	  to	  develop	  forecasting	  methods	  in	  order	  to	  develop	  appropriate	  interventions	  
and	  plan	  health	  services	  (Checkley	  et	  al.	  2000).	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II.	  	  FIRST	  PAPER:	  EPIDEMIOLOGY	  AND	  GENETIC	  CHARACTERIZATION	  OF	  
NOROVIRUSES	  AMONG	  ADULT	  PERUVIAN	  MILITARY	  PERSONNEL	  IN	  AN	  
ENDEMIC	  SETTING,	  AMAZON	  BASIN,	  2004-­‐2011	  
	  
ABSTRACT	  
Successful	  vaccination	  strategies	  against	  norovirus	  will	  require	  understanding	  the	  
burden	  of	  disease	  and	  relevant	  genotypes	  in	  populations.	  However,	  few	  data	  are	  
available	  from	  cohort	  studies	  of	  adults	  living	  in	  low-­‐	  and	  middle-­‐income	  countries	  
(LMIC).	  We	  conducted	  a	  nested	  case-­‐control	  study	  within	  a	  Peruvian	  military	  cohort	  
to	  characterize	  the	  burden	  of	  norovirus	  infection,	  predominant	  genotypes,	  and	  
associated	  symptoms	  from	  2004	  through	  2011.	  	  Randomly	  selected	  case	  and	  control	  
stools	  were	  tested	  for	  norovirus,	  bacteria,	  and	  parasites.	  	  The	  odds	  ratio	  of	  the	  
association	  between	  norovirus	  infection	  and	  diarrhea	  was	  estimated	  using	  multiple	  
logistic	  regression	  and	  co-­‐infection	  adjusted	  attributable	  fractions	  were	  calculated.	  
Of	  the	  3,818	  cohort	  study	  participants,	  624	  developed	  diarrhea.	  Overall	  and	  
norovirus-­‐associated	  diarrhea	  incidence	  rates	  were	  42.3	  and	  6.0	  per	  100	  person-­‐
years,	  respectively.	  The	  most	  prevalent	  norovirus	  genogroup	  was	  GII	  (72.5%,	  
29/40),	  which	  was	  associated	  with	  diarrhea	  (AOR	  3.4,	  95%	  CI:	  1.3-­‐8.7,	  P=0.012).	  
The	  co-­‐infection	  adjusted	  GII	  attributable	  fraction	  was	  6.4%.	  Norovirus	  was	  a	  
frequent	  cause	  of	  diarrhea	  in	  an	  adult	  population	  followed	  longitudinally	  in	  an	  LMIC	  
setting.	  	  Vaccine	  strategies	  should	  consider	  targeting	  adults	  in	  endemic	  settings	  and	  





Norovirus,	  family	  Caliciviridae,	  causes	  nearly	  half	  of	  all	  acute	  gastroenteritis	  cases	  
worldwide	  (Patel	  et	  al.	  2009).	  Norovirus	  infects	  people	  of	  all	  ages;	  however,	  the	  
majority	  of	  reported	  data	  come	  from	  pediatric	  populations	  or	  outbreaks	  in	  adults	  
from	  high-­‐income	  countries.	  	  In	  adults,	  norovirus	  infections	  have	  been	  well	  
described	  in	  travelers	  (Atmar	  and	  Estes	  2006)	  and	  persons	  working	  (Ben	  A.	  Lopman	  
et	  al.	  2004)	  or	  residing	  in	  hospitals	  (Kaufman	  et	  al.	  2005)	  military	  camps	  (Chapman	  
et	  al.	  2011)	  aboard	  ships	  (Cramer,	  Gu,	  and	  Durbin	  2003;	  Riddle	  et	  al.	  2004),	  and	  in	  
other	  closed	  environments	  (Patel	  et	  al.	  2009).	  However,	  conclusions	  from	  these	  
studies	  may	  not	  be	  generalizable	  to	  at-­‐risk	  adults	  from	  low-­‐	  and	  middle-­‐income	  
countries	  (LMIC),	  where	  norovirus	  infections	  occur	  at	  a	  young	  age,	  and	  reinfection	  
occurs	  frequently	  thereafter	  (Saito	  et	  al.	  2014).	  	  
	  
Noroviruses	  can	  be	  classified	  into	  six	  different	  phylogenetic	  clades,	  or	  genogroups	  
(GI-­‐GVI)	  (Glass,	  Parashar,	  and	  Estes	  2009).	  	  Viruses	  from	  GI,	  GII	  and,	  much	  less	  
frequently,	  GIV	  cause	  human	  disease.	  Norovirus	  genogroups	  are	  further	  classified	  
into	  genotypes,	  and	  genotype	  GII.4	  is	  further	  classified	  into	  variants	  (Glass,	  
Parashar,	  and	  Estes	  2009).	  The	  emergence	  of	  novel	  GII.4	  variants	  has	  initiated	  all	  six	  
norovirus-­‐associated	  acute	  gastroenteritis	  pandemics	  noted	  since	  1995	  (Glass,	  
Parashar,	  and	  Estes	  2009).	  
	  
Given	  recent	  advances	  in	  the	  development	  of	  norovirus	  candidate	  vaccines,	  there	  is	  
a	  need	  to	  estimate	  the	  burden	  of	  norovirus–associated	  disease	  in	  populations	  at	  risk	  
for	  acute	  gastroenteritis	  worldwide,	  as	  well	  as	  to	  determine	  the	  predominant	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norovirus	  genotypes	  and	  their	  associated	  pathogenicity	  (Bernstein	  et	  al.	  2015;	  El‐
Kamary	  et	  al.	  2010;	  Ramani	  et	  al.	  2017;	  Blazevic	  et	  al.	  2011).	  	  However,	  there	  is	  
limited	  information	  about	  the	  burden	  of	  norovirus-­‐associated	  adult	  gastroenteritis	  
in	  LMIC	  settings.	  Therefore,	  we	  conducted	  a	  nested	  case-­‐control	  study	  within	  a	  
cohort	  of	  Peruvian	  military	  personnel	  in	  the	  Amazon	  Basin	  to	  characterize	  the	  
burden	  of	  norovirus	  infection,	  predominant	  genotypes,	  and	  associated	  symptoms	  in	  
adults	  followed	  longitudinally	  in	  an	  LMIC	  setting.	  	  
	  
METHODS	  
Ethics	  Statement.	  	  This	  study	  was	  approved	  by	  the	  Naval	  Medical	  Research	  Unit	  No.	  
6	  Institutional	  Review	  Board	  and	  the	  military	  command	  at	  Vargas	  Guerra	  Army	  
base.	  	  Participants	  provided	  written	  informed	  consent.	  	  	  
	  
Parent	  cohort	  study.	  Between	  January	  1,	  2002,	  and	  December	  31,	  2011,	  the	  United	  
States	  Naval	  Medical	  Research	  Unit	  No.	  6	  (NAMRU-­‐6)	  conducted	  surveillance	  for	  
acute	  diarrhea	  among	  military	  personnel	  at	  the	  Vargas	  Guerra	  Army	  base,	  Iquitos,	  
Peru	  (Figure	  1).	  Diarrhea	  was	  defined	  as	  three	  or	  more	  loose	  or	  watery	  stools	  or	  
two	  loose	  or	  watery	  stools	  accompanied	  by	  nausea,	  vomiting,	  abdominal	  
cramps/pain,	  or	  tenesmus	  within	  the	  preceding	  24	  hours,	  a	  modified	  definition	  from	  
(Scallan	  et	  al.	  2004;	  Majowicz	  et	  al.	  2008).	  After	  at	  least	  seven	  days	  without	  diarrhea	  
following	  enrollment	  in	  the	  cohort	  study,	  asymptomatic	  participants	  provided	  basic	  
demographic	  information	  and	  a	  stool	  sample	  (“baseline	  stool”).	  Passive	  surveillance	  
(i.e.	  recording	  of	  persons	  presenting	  to	  the	  health	  center)	  for	  diarrhea	  was	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conducted	  until	  February	  1,	  2004,	  after	  which	  a	  study	  nurse	  conducted	  active	  
surveillance,	  screening	  each	  participant	  daily	  for	  diarrhea.	  If	  a	  participant	  met	  the	  
case	  definition,	  the	  study	  nurse	  recorded	  the	  patient’s	  oral	  temperature,	  
administered	  a	  symptom	  questionnaire,	  and	  collected	  a	  fresh	  stool	  sample.	  At	  the	  
conclusion	  of	  each	  diarrhea	  episode,	  the	  study	  nurse	  questioned	  the	  participant	  
about	  the	  episode’s	  impact	  on	  daily	  activities.	  	  Impact	  was	  classified	  as	  mild	  if,	  as	  a	  
result	  of	  the	  episode,	  the	  participant	  experienced	  no	  change	  in	  daily	  plans;	  moderate	  
if	  the	  participant	  experienced	  an	  alteration	  in	  daily	  activities	  but	  did	  not	  miss	  work;	  
or	  severe	  if	  the	  participant	  missed	  at	  least	  part	  of	  the	  work	  day.	  Two	  milliliters	  of	  
fresh	  stool	  were	  separated	  for	  storage	  at	  -­‐80oC	  for	  future	  norovirus	  testing	  and	  the	  
remainder	  sent	  to	  the	  NAMRU-­‐6	  laboratory	  in	  Iquitos	  for	  bacteriological	  and	  
parasitological	  evaluation	  as	  described	  below.	  	  	  	  	  
	  
Nested	  case-­‐control	  study.	  Within	  the	  described	  cohort,	  we	  conducted	  a	  nested	  
case-­‐control	  study	  using	  stool	  samples	  and	  data	  collected	  from	  participants	  who	  
enrolled	  in	  the	  study	  during	  the	  active	  surveillance	  period	  from	  February	  1,	  2004,	  
through	  December	  31,	  2011.	  Cases	  were	  participants	  with	  a	  first	  episode	  of	  
diarrhea,	  as	  defined	  above.	  	  Controls	  were	  participants	  who	  were	  asymptomatic	  at	  
the	  time	  of	  stool	  collection.	  We	  randomly	  selected	  200	  cases	  and	  200	  controls	  for	  
inclusion	  in	  the	  nested	  case-­‐control	  study.	  	  
	  
Norovirus	  detection	  and	  sequencing.	  A	  suspension	  of	  each	  stored	  stool	  specimen	  
(10%	  wt/vol)	  was	  prepared	  in	  phosphate	  buffered	  saline	  and	  RNA	  extracted	  using	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the	  Qiagen	  QIAmp	  viral	  RNA	  kit	  (Valencia,	  CA)	  in	  accordance	  with	  the	  
manufacturer’s	  instructions.	  Viral	  RNA	  was	  tested	  for	  norovirus	  GI	  and	  GII	  by	  real-­‐
time	  polymerase	  chain	  reaction	  (PCR)	  (Apaza	  et	  al.	  2012).	  A	  sample	  was	  considered	  
positive	  if	  the	  negative	  control	  did	  not	  exhibit	  fluorescent	  curves.	  The	  threshold	  
cycle	  for	  the	  sample	  was	  at	  least	  37	  for	  norovirus	  GI	  and	  39	  for	  GII.	  Positive	  samples	  
were	  then	  genotyped	  by	  sequencing	  Region	  C	  within	  the	  capsid	  gene	  after	  
conventional	  PCR	  and	  gel-­‐purification	  of	  amplicons,	  comparing	  results	  with	  
norovirus	  prototypic	  strains	  using	  the	  NoroNet	  sequence	  typing	  tool	  (Kroneman	  et	  
al.	  2011).	  
	  
Bacteria	  and	  parasite	  detection.	  At	  the	  time	  of	  collection,	  fresh	  stool	  specimens	  
were	  transported	  in	  Cary-­‐Blair	  medium	  and	  wide-­‐mouthed	  containers	  to	  the	  
NAMRU-­‐6	  laboratory	  in	  Iquitos	  for	  bacteria	  and	  parasite	  analysis,	  respectively.	  
Escherichia	  coli	  and	  Salmonella,	  Shigella,	  Yersinia,	  and	  Campylobacter	  spp.	  were	  
cultured	  and	  isolated	  as	  previously	  described	  (Gray	  1995;	  Nachamkin	  1999).	  
Polymerase	  chain	  reaction	  for	  heat	  labile	  and	  stable	  enterotoxigenic	  E.	  coli	  (ETEC)	  
was	  performed	  on	  five	  lactose-­‐fermenting	  colonies	  morphologically	  resembling	  E.	  
coli	  (Stacy-­‐Phipps,	  Mecca,	  and	  Weiss	  1995).	  Plesiomonas	  spp.	  were	  identified	  using	  
the	  method	  of	  Hugh	  (Hugh	  1970).	  Vibrio	  cholerae	  were	  isolated	  using	  thiosulfate	  
citrate	  bile	  salts	  sucrose	  agar	  (Laboratory	  Methods	  for	  the	  Diagnosis	  of	  Vibrio	  
Cholerae:	  Isolation	  of	  Vibrio	  Cholerae	  from	  Fecal	  Specimens	  2016).	  Microscopy	  for	  
ova	  and	  parasites	  was	  performed	  on	  saline	  wet	  preparations	  to	  detect	  protozoa	  and	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helminth	  infections.	  The	  ether	  sedimentation	  technique	  was	  used	  to	  microscopically	  
identify	  Giardia	  spp	  (Ritchie	  1948).	  
	  
Statistical	  methods.	  The	  2-­‐tailed	  Student	  t	  test	  was	  used	  for	  comparison	  of	  
continuous	  outcome	  variable	  means.	  Proportions	  were	  compared	  using	  Fisher’s	  
exact	  test.	  The	  relationship	  between	  dichotomous	  clinical	  signs	  and	  symptoms	  of	  
gastroenteritis	  and	  predictor	  variables	  was	  assessed	  using	  univariate	  logistic	  
regression.	  A	  sensitivity	  analysis	  was	  performed	  by	  re-­‐classifying	  the	  norovirus-­‐
bacterial	  co-­‐infections	  as	  norovirus	  negative	  and	  repeating	  the	  multivariate	  logistic	  
regression	  analysis	  of	  the	  relationship	  between	  norovirus	  infection	  and	  diarrheal	  
disease.	  Norovirus	  pathogenicity	  indices	  (ratio	  of	  the	  prevalence	  of	  norovirus	  in	  
diarrheal	  stools/prevalence	  in	  baseline)	  were	  calculated.	  
	  
The	  statistical	  analysis	  for	  predictors	  of	  diarrhea	  was	  performed	  in	  several	  steps;	  
first,	  the	  association	  of	  diarrhea	  with	  specific	  pathogens	  was	  evaluated	  using	  simple	  
and	  multiple	  logistic	  regression	  analyses.	  Conditional	  mean	  imputation	  was	  used	  to	  
handle	  missing	  exposure	  values.	  Variance	  inflation	  factors	  were	  all	  below	  zero.	  
Forward	  and	  backward	  stepwise	  selection	  was	  used	  to	  select	  variables	  for	  
regression	  models.	  Nested	  models	  were	  compared	  using	  likelihood	  ratio	  tests	  and	  
Akaike’s	  Information	  Criteria.	  When	  two	  nested	  models	  were	  compared	  using	  
likelihood	  ratio	  tests,	  only	  the	  cases	  common	  to	  both	  regression	  models	  following	  
model-­‐wise	  deletion	  were	  used	  for	  comparison.	  Potential	  interactions	  were	  
evaluated	  with	  regression	  models.	  We	  used	  adjusted	  odds	  ratios	  and	  pathogen	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prevalence	  among	  cases	  to	  calculate	  adjusted	  population	  attributable	  fractions	  
(AFs)	  to	  estimate	  the	  pathogen-­‐specific	  disease	  burden	  (Bruzzi	  et	  al.	  1985).	  The	  
adjusted	  AF	  is	  derived	  from	  the	  logistic	  regression	  model	  that	  includes	  other	  
pathogens	  significantly	  associated	  with	  diarrhea;	  thus,	  it	  is	  the	  AF	  adjusted	  for	  the	  
presence	  of	  other	  pathogens.	  Diarrhea	  was	  considered	  to	  be	  attributable	  to	  the	  
pathogen	  identified	  in	  stools	  collected	  at	  the	  time	  of	  a	  diarrhea	  episode.	  	  	  	  	  
	  
For	  diarrhea	  incidence	  calculations	  in	  the	  nested	  study,	  the	  average	  time	  to	  first	  
diarrhea	  episode	  was	  calculated	  for	  the	  randomly	  selected	  cases,	  and	  average	  time	  
of	  observation	  since	  enrollment	  or	  last	  diarrhea	  episode,	  whichever	  came	  first,	  was	  
calculated	  for	  the	  randomly	  selected	  controls.	  To	  estimate	  total	  person-­‐time	  
observed	  during	  the	  period	  of	  active	  surveillance,	  we	  multiplied	  these	  numbers	  by	  
the	  number	  of	  cases	  and	  controls,	  respectively,	  enrolled	  during	  this	  period.	  The	  
incidence	  of	  diarrhea	  was	  then	  calculated	  by	  dividing	  the	  number	  of	  cases	  by	  the	  
total	  person-­‐time.	  To	  calculate	  norovirus	  diarrhea	  incidence,	  the	  prevalence	  of	  
norovirus	  in	  stools	  from	  cases	  was	  multiplied	  by	  the	  diarrhea	  incidence.	  Two-­‐sided	  
p-­‐values	  less	  than	  0.05	  were	  considered	  statistically	  significant.	  	  STATA	  version	  12.1	  
(College	  Station,	  Texas)	  (Stata	  Data	  Analysis	  and	  Statistical	  Software	  2015)	  was	  





Parent	  cohort	  study.	  During	  the	  10-­‐year	  period	  of	  mixed	  active	  and	  passive	  
surveillance,	  4,234	  males	  aged	  18-­‐34	  were	  enrolled	  in	  the	  parent	  cohort	  study	  
(Figure	  2).	  	  Of	  these,	  643	  met	  the	  diarrhea	  case	  definition.	  	  	  
	  
Nested	  case-­‐control	  study.	  During	  the	  8-­‐year	  active	  surveillance	  period,	  3,194	  
participants	  were	  enrolled	  in	  the	  cohort,	  and	  624	  developed	  diarrhea	  (attack	  rate	  
19.5%).	  The	  incidence	  of	  diarrhea	  was	  42.3	  cases	  per	  100	  person-­‐years.	  	  The	  200	  
randomly	  selected	  diarrhea	  cases	  and	  200	  randomly	  selected	  controls	  were	  roughly	  
evenly	  distributed	  over	  the	  study	  period	  (data	  not	  shown).	  	  Of	  these,	  184	  case	  and	  
176	  control	  stools	  were	  available	  for	  norovirus	  analysis.	  Norovirus	  was	  identified	  in	  
14.1%	  (26/184)	  and	  8.0%	  (14/176)	  of	  stool	  samples	  from	  cases	  and	  controls,	  
respectively	  (Table	  1).	  The	  norovirus-­‐associated	  diarrhea	  attack	  rate	  was	  2.7%	  
(14.1%	  prevalence	  of	  norovirus	  in	  case	  stools	  *	  19.5%	  diarrhea	  attack	  rate)	  with	  an	  
incidence	  of	  6.0	  norovirus	  diarrhea	  cases	  per	  100	  person-­‐years.	  The	  norovirus	  
pathogenicity	  indices	  were	  1.4	  for	  GI,	  2.1	  for	  GII,	  and	  1.8	  overall.	  	  
	  
Diarrhea	  cases	  had	  a	  higher	  prevalence	  of	  ETEC	  (P=0.001)	  and	  Shigella	  spp.	  
(P<0.001)	  relative	  to	  controls,	  but	  a	  lower	  prevalence	  of	  Trichuris	  (P=0.006)	  (Table	  
1,	  S1	  Dataset).	  Multiple	  logistic	  regression	  analysis	  revealed	  norovirus	  infection	  to	  
be	  significantly	  associated	  with	  diarrhea	  (AOR	  2.8,	  95%	  CI:	  1.3-­‐6.0,	  P=0.008).	  
However,	  when	  stratified	  by	  genogroup,	  this	  relationship	  only	  remained	  significant	  
for	  norovirus	  GII	  (P=0.012).	  The	  norovirus	  GI	  variable	  was	  subsequently	  dropped	  
from	  the	  adjusted	  model	  (Table	  2).	  Other	  variables	  associated	  with	  diarrhea	  in	  the	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adjusted	  norovirus	  GII	  model	  were	  infection	  with	  Shigella	  spp.	  (P<0.001),	  ETEC	  
(P=0.004),	  and	  Trichuris	  (P=0.005),	  the	  latter	  being	  associated	  with	  a	  decreased	  risk	  
of	  diarrhea.	  After	  reclassifying	  norovirus-­‐bacteria	  co-­‐infected	  individuals	  as	  
norovirus-­‐negative	  in	  the	  sensitivity	  analysis,	  the	  relationship	  between	  GII	  infection	  
and	  diarrhea	  remained	  statistically	  significant	  in	  the	  adjusted	  multiple	  logistic	  
regression	  model	  (AOR	  2.7,	  CI:	  1.0-­‐7.1,	  P=0.047).	  The	  AFs	  for	  norovirus	  GII,	  Shigella	  
spp.,	  and	  ETEC	  were	  6.4%	  (95%	  CI:	  1.0-­‐9.0%),	  18.2%	  (95%	  CI:	  14.3-­‐20.0%),	  and	  
7.1%	  (95%	  CI:	  3.8-­‐7.9%),	  respectively.	  	  	  
	  
Of	  all	  noroviruses	  identified,	  30.0%	  (12/40)	  were	  GI,	  72.5%	  (29/40)	  were	  GII,	  and	  
2.5%	  (1/40)	  were	  mixed	  GI/GII	  infections.	  Twenty-­‐five	  (61.0%)	  of	  the	  41	  norovirus	  
isolates	  could	  be	  genotyped	  (18	  from	  cases	  and	  7	  from	  controls),	  of	  which	  11	  were	  
norovirus	  GI	  and	  14	  were	  GII	  (Table	  3).	  The	  predominant	  norovirus	  GI	  and	  GII	  
genotypes	  were	  GI.4	  (7	  stools)	  and	  GII.4	  (6	  stools).	  	  
	  
Among	  all	  norovirus-­‐infected	  participants,	  co-­‐infection	  with	  norovirus	  and	  one	  or	  
more	  organisms	  was	  present	  in	  67.5%	  (27/40),	  including	  12.5%	  (5/40)	  of	  
participants	  infected	  with	  norovirus	  and	  three	  other	  organisms.	  Norovirus	  co-­‐
infection	  was	  most	  often	  with	  chronically	  carried	  soil-­‐transmitted	  helminths	  (n=9),	  
Giardia	  (n=5),	  or	  both	  (n=2),	  although	  co-­‐infection	  with	  norovirus	  and	  either	  
Shigella	  (n=4)	  or	  ETEC	  (n=4)	  was	  also	  noted	  (Table	  4).	  Trichuris	  was	  less	  frequently	  
found	  in	  cases	  (15.3%,	  30/196)	  relative	  to	  controls	  (16.8%,	  52/194)	  (P=0.006).	  
However,	  among	  diarrhea	  cases,	  Trichuris	  was	  more	  frequent	  in	  GII-­‐positive	  stools	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(30.0%,	  6/20)	  relative	  to	  GII-­‐negative	  ones	  (12.4%,	  20/161)	  (P=0.046).	  No	  other	  
statistically	  significant	  associations	  were	  noted.	  	  
	  
Of	  norovirus	  positive	  cases,	  23.5%	  (6/26)	  reported	  that	  their	  symptoms	  had	  
minimal	  impact	  on	  their	  daily	  activities,	  73.1%	  (19/26)	  reported	  a	  moderate	  impact,	  
and	  3.8%	  (1/26)	  reported	  a	  severe	  impact.	  None	  of	  the	  participants	  were	  
hospitalized	  and	  there	  were	  no	  deaths.	  There	  was	  no	  significant	  difference	  in	  the	  
frequency	  of	  clinical	  symptoms	  associated	  with	  norovirus	  diarrhea	  compared	  to	  
other	  etiologies.	  Infection	  with	  norovirus	  GII	  produced	  more	  severe	  disease	  than	  
norovirus	  GI,	  reaching	  statistical	  significance	  for	  abdominal	  pain	  (94.7%,	  18/19	  
versus	  50.0%,	  3/6,	  P=0.031)	  (Table	  5).	  	  	  
	  
DISCUSSION	  
Norovirus	  infection	  was	  the	  second	  most	  common	  diarrheagenic	  pathogen	  detected	  
in	  our	  study.	  The	  virus,	  especially	  norovirus	  GI,	  was	  also	  frequently	  present	  in	  stools	  
of	  persons	  who	  had	  not	  recently	  experienced	  diarrhea,	  as	  has	  been	  frequently	  
reported	  (Lindesmith	  et	  al.	  2008).	  Furthermore,	  co-­‐infection	  with	  norovirus	  and	  
other	  enteric	  organisms	  was	  frequent.	  In	  this	  pathogen	  diverse	  setting	  it	  can	  be	  
difficult	  to	  determine	  the	  specific	  etiologic	  agent	  of	  a	  case	  of	  diarrhea.	  Nevertheless,	  
the	  pathogenicity	  index	  of	  norovirus,	  particularly	  the	  GII	  genogroup,	  was	  high	  
relative	  to	  other	  major	  enteric	  pathogens.	  Norovirus	  was	  the	  sole	  pathogen	  in	  27.0%	  
of	  norovirus-­‐infected	  diarrhea	  cases	  and	  69.2%	  of	  norovirus	  diarrheal	  cases	  did	  not	  
have	  a	  co-­‐infecting	  bacterial	  pathogen.	  Together,	  these	  observations	  suggest	  that	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norovirus	  is	  the	  cause	  of	  the	  majority	  of	  the	  diarrheal	  illness	  with	  which	  it	  is	  
associated	  and	  a	  major	  cause	  of	  diarrhea	  in	  the	  study	  population.	  Possible	  reasons	  
for	  the	  presence	  of	  norovirus	  in	  baseline	  stools	  include	  continued	  shedding	  in	  
persons	  recovering	  from	  a	  bout	  of	  diarrhea	  experienced	  before	  the	  wash-­‐out	  period	  
(norovirus,	  particularly	  GII,	  can	  be	  shed	  for	  weeks	  to	  months	  after	  an	  episode	  of	  
diarrhea)	  (Atmar	  and	  Estes	  2006;	  Saito	  et	  al.	  2014),	  asymptomatic	  infection	  due	  to	  
pre-­‐existing	  innate	  or	  acquired	  immunity,	  and	  insufficient	  infectious	  dose.	  	  
	  
Few	  studies	  have	  described	  the	  disease	  burden	  of	  norovirus	  in	  adults	  in	  LMIC	  
settings.	  The	  burden	  of	  acute	  diarrhea	  attributable	  to	  norovirus	  noted	  in	  our	  study	  
is	  similar	  to	  that	  noted	  in	  children	  in	  Peru	  (Saito	  et	  al.	  2014;	  Pablo	  Peñataro	  Yori	  et	  
al.	  2009),	  although	  the	  risk	  of	  infection	  in	  our	  closed	  population	  on	  a	  military	  base	  is	  
likely	  higher	  than	  that	  typically	  noted	  in	  adults	  in	  the	  community	  due	  to	  the	  military	  
base’s	  relatively	  increased	  population	  density,	  poor	  sanitation	  and	  hygiene,	  and	  the	  
resultant	  increased	  burden	  of	  norovirus	  contamination	  of	  the	  environment.	  
Interestingly,	  in	  a	  rural	  community-­‐based	  study	  of	  norovirus	  by	  Peñataro	  Yori	  et	  al	  
in	  children	  in	  the	  same	  region	  as	  our	  study	  site,	  the	  proportion	  of	  diarrheal	  cases	  
attributable	  to	  norovirus	  was	  highly	  age	  dependent,	  accounting	  for	  22-­‐25%	  in	  
children	  0-­‐2	  years	  old	  but	  steadily	  falling	  with	  age,	  accounting	  for	  less	  than	  5%	  by	  
age	  4-­‐5	  years	  (Pablo	  Peñataro	  Yori	  et	  al.	  2009).	  The	  authors	  concluded	  that	  
naturally	  acquired	  immunity	  protected	  children	  as	  they	  age.	  However,	  our	  results	  
suggest	  that	  many	  adults	  remain	  susceptible	  to	  infection	  and	  disease	  from	  
norovirus.	  We	  cannot	  determine	  whether	  the	  cases	  of	  norovirus	  diarrhea	  in	  our	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study	  resulted	  from	  viral	  evolution	  for	  immune	  escape	  or	  first	  infection	  in	  naïve	  
hosts,	  although	  given	  that	  norovirus	  infection	  in	  children	  is	  nearly	  universal	  in	  Peru	  
(Saito	  et	  al.	  2014),	  we	  highly	  suspect	  the	  former.	  The	  specific	  norovirus	  genotypes	  
circulating	  at	  the	  time	  of	  each	  study	  may	  also	  play	  a	  role,	  as	  immunity	  is	  likely	  
genotype-­‐specific	  (Patel	  et	  al.	  2009).	  Norovirus	  genotypes	  were	  not	  determined	  in	  
the	  Peñataro	  Yori	  et	  al	  study.	  Another	  possible	  factor	  that	  could	  contribute	  to	  
variable	  susceptibility	  of	  adults	  to	  norovirus-­‐induced	  diarrhea,	  not	  determined	  in	  
either	  study,	  is	  histo-­‐blood	  antigen	  group,	  which	  appears	  to	  mediate	  norovirus-­‐
binding	  through	  epithelial	  cell	  surface	  ligands	  (Lindesmith	  et	  al.	  2008).	  It	  is	  also	  
worth	  noting	  that	  Yori	  et	  al	  reported	  fever	  in	  71.4%	  of	  children	  with	  norovirus-­‐
associated	  diarrhea	  versus	  none	  of	  the	  adults	  in	  our	  study,	  suggesting	  that	  at	  least	  
some	  clinical	  features	  of	  norovirus	  infection	  may	  be	  age	  dependent,	  or	  perhaps	  
change	  with	  successive	  norovirus	  infections.	  	  
	  	  
A	  successful	  norovirus	  vaccine	  will	  need	  to	  provide	  protection	  against	  various	  
norovirus	  genogroups	  and	  types	  (Daniel	  C.	  Payne	  et	  al.	  2013).	  Our	  investigation	  
provides	  detailed	  data	  on	  the	  norovirus	  genotypes	  circulating	  in	  the	  study	  region.	  As	  
with	  many	  other	  studies,	  we	  found	  norovirus	  GII	  to	  be	  a	  prevalent	  and	  particularly	  
pathogenic	  genotype	  (especially	  GII.4),	  suggesting	  that	  it	  should	  be	  at	  least	  one	  
major	  target	  of	  a	  norovirus	  vaccine.	  Similar	  findings	  have	  been	  reported	  in	  Brazil,	  
Argentina,	  and	  Bolivia	  (Blanco	  Fernández	  et	  al.	  2011;	  Ferreira	  et	  al.	  2010;	  McAtee	  et	  
al.	  2016).	  Previous	  research	  has	  shown	  that,	  compared	  with	  persons	  infected	  with	  
other	  norovirus	  genotypes,	  those	  infected	  with	  norovirus	  GII.4	  shed	  the	  virus	  in	  
 
	  30	  
larger	  numbers	  (Lee	  et	  al.	  2007),	  transmit	  the	  virus	  at	  higher	  rates	  (Lee	  et	  al.	  2007),	  
and	  have	  poorer	  outcomes	  (Desai	  et	  al.	  2012).	  Further	  investigation	  of	  the	  
noroviruses	  that	  we	  were	  unable	  to	  genotype	  will	  be	  important	  to	  fully	  understand	  
the	  epidemiology	  and	  the	  organisms	  and	  epitopes	  relevant	  to	  a	  successful	  vaccine.	  	  
	  
The	  range	  of	  organisms	  and	  co-­‐infections	  noted	  in	  our	  study	  is	  similar	  to	  that	  
previously	  reported	  in	  both	  children	  and	  adults	  in	  the	  region	  (Pablo	  Peñataro	  Yori	  
et	  al.	  2009;	  Jones	  et	  al.	  2004).	  Interestingly,	  co-­‐infection	  with	  Trichuris	  was	  
associated	  with	  a	  decreased	  risk	  of	  diarrhea	  in	  persons	  also	  infected	  with	  norovirus.	  	  
Trichuris	  co-­‐infection	  in	  children	  has	  been	  documented	  with	  numerous	  enteric	  
organisms,	  including	  Entamoeba	  histolytica	  (Jung	  and	  Beaver	  1951),	  Shigella	  spp.	  
(Gilman,	  Davis,	  and	  Fitzgerald	  1976),	  Salmonella	  spp.	  (Gilman,	  Davis,	  and	  Fitzgerald	  
1976),	  and	  a	  variety	  of	  helminths	  (Lello	  et	  al.	  2013).	  We	  speculate	  that	  Trichuris	  
infection	  in	  our	  population	  serves	  as	  a	  proxy	  for	  frequent	  previous	  infection	  and	  
consequent	  enhanced	  immunity	  to	  enteric	  pathogens,	  including	  noroviruses.	  The	  
apparent	  lack	  of	  a	  protective	  effect	  of	  Trichuris	  infection	  against	  norovirus	  GII	  
infection	  relative	  to	  GI	  infection	  may	  relate	  to	  the	  increased	  mutation	  rate	  and	  thus	  
genetic	  variability	  of	  the	  norovirus	  GII	  genogroup,	  allowing	  these	  viruses	  to	  present	  
varied	  epitopes	  that	  escape	  immune	  system	  detection	  (Glass,	  Parashar,	  and	  Estes	  
2009).	  
	  
Limitations	  to	  our	  study	  include	  the	  1)	  Lack	  of	  a	  validated	  diarrhea	  severity	  score	  
for	  adults,	  which	  limited	  our	  ability	  to	  evaluate	  the	  relationship	  between	  norovirus	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infection	  and	  disease	  severity;	  2)	  Use	  of	  a	  case	  definition	  that	  did	  not	  include	  
vomiting	  without	  diarrhea,	  which	  is	  common	  with	  norovirus	  infection,	  which	  could	  
result	  in	  underestimation	  of	  the	  contribution	  of	  norovirus	  to	  gastroenteritis	  in	  the	  
study	  population;	  3)	  Short	  (1-­‐week)	  washout	  period	  before	  baseline	  stool	  
evaluation,	  which	  could	  result	  in	  underestimation	  of	  the	  norovirus	  pathogenicity	  
index,	  given	  that	  norovirus	  may	  be	  shed	  for	  a	  median	  of	  28	  days	  in	  adults	  following	  
acute	  infection	  (Atmar	  et	  al.	  2008);	  4)	  Use	  of	  qualitative	  rather	  than	  quantitative	  
PCR,	  precluding	  exploration	  of	  possible	  associations	  between	  viral	  load	  and	  disease;	  
5)	  Use	  of	  conventional	  PCR,	  which	  is	  less	  sensitive	  than	  rRT-­‐PCR,	  to	  obtain	  material	  
for	  genetic	  sequencing,	  which	  could	  have	  biased	  detection	  toward	  norovirus	  
genotypes	  and	  variants	  present	  in	  higher	  viral	  loads	  (Table	  3).	  Nor	  would	  our	  
methodology	  detect	  norovirus	  GIV;	  6)	  Lack	  of	  data	  on	  the	  precise	  duration	  of	  each	  
participant	  on	  the	  base,	  which	  may	  have	  led	  to	  overestimation	  of	  the	  person-­‐time	  at	  
risk	  and	  an	  underestimation	  of	  incidence	  rates;	  and	  7)	  Small	  sample	  size,	  which	  
often	  limited	  statistical	  analysis	  of	  the	  temporal	  distribution	  and	  disease	  
associations	  of	  specific	  norovirus	  genotypes	  and	  variants.	  This	  latter	  point	  is	  
especially	  important	  considering	  that	  norovirus	  pandemics	  featuring	  novel	  variants	  
occur	  every	  two	  to	  four	  years	  (Glass,	  Parashar,	  and	  Estes	  2009).	  Rapid	  norovirus	  
mutation	  and	  recombination	  events	  may	  result	  in	  the	  development	  of	  novel	  
norovirus	  genotypes	  and	  variants,	  particularly	  in	  the	  GII	  genogroup,	  in	  a	  manner	  
similar	  to	  that	  of	  the	  influenza	  A	  virus	  (Lam	  et	  al.	  2012).	  In	  settings	  where	  norovirus	  
is	  prevalent,	  mutations	  may	  occur	  at	  an	  accelerated	  pace,	  leading	  to	  the	  emergence	  




In	  conclusion,	  our	  study	  helps	  extend	  knowledge	  of	  the	  complex	  epidemiology	  of	  
adult	  norovirus	  infection	  and	  disease	  in	  a	  closed	  setting	  in	  a	  LMIC.	  	  Such	  
populations,	  which	  are	  traditionally	  prone	  to	  norovirus	  outbreaks	  with	  high	  
transmission	  rates,	  could	  serve	  as	  potential	  sources	  of	  introduction	  into	  the	  
community	  and	  thus	  must	  be	  considered	  in	  future	  control	  and	  vaccination	  
strategies.	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III.	  	  SECOND	  PAPER:	  APPLICATION	  OF	  A	  RELATIVE	  COST-­‐EFFECTIVENESS	  
ANALYSIS	  MODEL	  TO	  THE	  EVALUATION	  OF	  PATHOGEN-­‐SPECIFIC	  VACCINES	  
AGAINST	  CAMPYLOBACTER,	  ETEC,	  SHIGELLA,	  AND	  NOROVIRUS	  TO	  A	  PERUVIAN	  
ADULT	  MILITARY	  POPULATION	  IN	  THE	  AMAZON	  BASIN	  	  
	  
ABSTRACT	  
Adult	  populations	  in	  low-­‐	  and	  middle-­‐income	  countries	  (LMIC)	  are	  often	  neglected	  
during	  the	  vaccine	  implementation	  planning	  process.	  We	  adapted	  an	  economic	  
model	  developed	  by	  the	  United	  States	  Department	  of	  Defense	  (DoD)	  to	  evaluate	  the	  
cost-­‐effectiveness	  of	  a	  vaccine	  acquisition	  strategy	  and	  modified	  for	  Campylobacter-­‐,	  
ETEC-­‐,	  Shigella-­‐,	  and	  norovirus-­‐associated	  gastroenteritis.	  We	  compared	  the	  cost-­‐
effectiveness	  of	  vaccine	  implementation	  with	  current	  medical	  management	  in	  the	  
Peruvian	  military,	  a	  special	  population	  of	  LMIC	  adults	  with	  a	  high	  incidence	  of	  
infectious	  diarrhea.	  Using	  US$	  per	  Duty	  Day	  Lost	  as	  an	  outcome	  measure,	  we	  found	  
that,	  relative	  to	  implementation	  in	  the	  United	  States,	  Shigella	  vaccine	  
implementation	  is	  significantly	  more	  cost-­‐effective	  for	  the	  Peruvian	  military	  
(CERDDL=$350	  versus	  $1275),	  and	  norovirus	  vaccine	  implementation	  is	  moderately	  
more	  cost	  effective	  (CERDDL=$926	  versus	  $1344).	  These	  data	  suggest	  that	  future	  
pathogen-­‐specific	  gastroenteritis	  vaccine	  acquisition	  strategies	  for	  the	  Peruvian	  
military	  may	  consider	  protecting	  troops	  against	  these	  pathogens.	  	  	  
	  
INTRODUCTION	  
While	  frequently	  discussed	  in	  the	  context	  of	  child	  mortality	  in	  low-­‐	  and	  middle-­‐
income	  countries	  (LMIC),	  acute	  gastroenteritis	  also	  contributes	  significantly	  to	  adult	  
disease	  in	  these	  settings	  (Ballard,	  Reaves,	  et	  al.	  2015a).	  In	  Peru,	  the	  incidence	  of	  
acute	  gastroenteritis	  among	  military	  troops	  deployed	  to	  the	  Amazon	  Basin	  was	  42.3	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per	  100	  person-­‐years	  (Ballard,	  Reaves,	  et	  al.	  2015a),	  while	  the	  Peruvian	  military’s	  
electronic	  syndromic	  surveillance	  system	  identified	  21.5	  cases	  of	  acute	  
gastroenteritis	  per	  100	  person-­‐years	  for	  adult	  active	  duty	  and	  reserve	  service	  
members,	  dependents,	  and	  civilian	  employees	  in	  garrison.	  Among	  Peruvian	  troops	  
deployed	  to	  the	  Amazon	  Basin	  (Alsentzer	  et	  al.	  2014),	  the	  most	  frequently	  isolated	  
non-­‐parasitic	  gastroenteritis-­‐associated	  pathogens	  were	  Shigella	  (22%),	  norovirus	  
(14%),	  enterotoxigenic	  Escherichia	  coli	  (ETEC)	  (8%),	  Salmonella	  (2%),	  Plesiomonas	  
(1%),	  Vibrio	  (0.5%),	  and	  Campylobacter	  (0.5%)	  (Ballard,	  Reaves,	  et	  al.	  2015a).	  
Vaccines	  against	  specific	  gastroenteritis-­‐associated	  pathogens	  are	  rapidly	  
approaching	  the	  market.	  Preliminary	  analysis	  indicates	  potential	  benefit	  for	  
pediatric	  populations	  in	  LMIC	  settings	  (Mirelman	  et	  al.	  2015b),	  in	  addition	  to	  adult	  
travelers	  (Ballard,	  Saito,	  et	  al.	  2015a;	  Jennings,	  Tilley,	  Ballard,	  Villanueva,	  Costa,	  
Lopez,	  Steinberg,	  Giannina	  Luna,	  et	  al.	  2017)	  and	  military	  personnel	  from	  high-­‐
income	  countries	  (Tallant	  et	  al.	  2014a).	  However,	  the	  potential	  use	  of	  these	  vaccines	  
in	  adult	  populations	  in	  LMIC	  settings	  has	  not	  been	  well	  characterized.	  Here,	  we	  
calculate	  the	  cost-­‐effectiveness	  of	  implementing	  vaccines	  currently	  under	  
development	  for	  Campylobacter,	  ETEC,	  Shigella,	  and	  norovirus	  in	  a	  military	  
population	  in	  a	  low-­‐	  and	  middle-­‐income	  country	  setting.	  	  	  
	  
METHODS	  	  
Model	  overview.	  	  We	  adapted	  an	  economic	  model	  developed	  by	  the	  United	  States	  
Department	  of	  Defense	  (DoD)	  to	  evaluate	  the	  cost-­‐effectiveness	  of	  a	  vaccine	  
acquisition	  strategy	  and	  modified	  for	  Campylobacter-­‐,	  ETEC-­‐,	  Shigella-­‐,	  and	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norovirus-­‐associated	  gastroenteritis	  (Tallant	  et	  al.	  2014a;	  Riddle	  et	  al.	  2008).	  We	  
compared	  the	  cost-­‐effectiveness	  of	  vaccine	  implementation	  with	  current	  medical	  
management	  in	  the	  Peruvian	  military.	  In	  the	  model,	  vaccination	  could	  result	  in	  
susceptibility	  to	  specific	  pathogen-­‐associated	  gastroenteritis	  or	  protection.	  
Susceptible	  individuals	  had	  two	  possible	  outcomes	  upon	  infection:	  symptomatic	  
gastroenteritis	  or	  asymptomatic	  infection	  (Tallant	  et	  al.	  2014a).	  Symptomatic	  
individuals	  might	  seek	  or	  not	  seek	  medical	  evaluation,	  and	  those	  seeking	  evaluation	  
could	  be	  managed	  in	  three	  potential	  ways:	  no	  treatment,	  treatment	  provided	  by	  a	  
health-­‐care	  provider,	  or	  aeromedical	  evacuation	  for	  severe	  disease	  manifestations	  
(Tallant	  et	  al.	  2014a).	  	  	  
	  
We	  assumed	  that	  the	  Peruvian	  military	  would	  not	  be	  responsible	  for	  research	  and	  
development	  associated	  with	  vaccines	  against	  enteric	  diseases.	  Similar	  to	  the	  DoD	  
model,	  we	  assumed	  a	  one-­‐year	  time	  horizon,	  discounting	  costs	  to	  account	  for	  future	  
inflation.	  	  We	  assumed	  that	  vaccine	  administration	  would	  take	  place	  before	  each	  
deployment	  due	  to	  waning	  immunity.	  Pathogen-­‐specific	  enteric	  vaccine-­‐associated	  
costs	  included:	  purchase	  price	  of	  a	  two-­‐dose	  vaccine;	  administrative	  costs,	  such	  as	  
storage,	  logistics,	  delivery,	  and	  monitoring;	  and	  adverse	  event	  treatment	  costs.	  We	  
used	  previously	  published	  Peruvian	  vaccination	  program	  costs	  for	  these	  estimates	  
(A.	  D.	  Clark	  et	  al.	  2009).	  We	  assumed	  that	  these	  vaccines	  would	  not	  be	  purchased	  
unless	  they	  met	  minimal	  military	  parameter	  requirements	  for	  efficacy	  of	  80%.	  The	  
target	  Peruvian	  military	  population	  size	  was	  120,660,	  consistent	  with	  published	  
force	  strength	  estimates	  (“Global	  Fire	  Power”	  2016).	  We	  used	  a	  deployment	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duration	  of	  3.5	  months,	  consistent	  with	  mission	  estimates	  provided	  by	  the	  Peruvian	  
military	  liaison	  on	  the	  Norovirus	  Working	  Group.	  We	  appreciated	  all	  costs	  to	  their	  
current	  2013	  value	  using	  the	  Consumer	  Price	  Index.	  
	  
Estimates	  of	  norovirus-­‐specific	  probability	  estimates,	  pathogen	  incidence,	  and	  
costs	  for	  the	  Peruvian	  military	  (Table	  6).	  	  To	  adapt	  the	  model	  to	  the	  Peruvian	  
military	  population,	  we	  obtained	  probability	  estimates	  for	  current	  gastroenteritis	  
management	  approaches,	  military	  healthcare	  provider	  treatment	  types,	  and	  
pathogen-­‐specific	  gastroenteritis	  prevalence	  estimates	  from	  surveillance	  data	  
published	  by	  our	  working	  group	  (Ballard,	  Reaves,	  et	  al.	  2015a).	  We	  obtained	  
aeromedical	  evacuation	  and	  treatment	  cost	  data	  from	  the	  Peruvian	  military	  medical	  
liaison	  on	  the	  working	  group.	  As	  none	  of	  these	  pathogen-­‐specific	  vaccines	  with	  the	  
desired	  parameters	  are	  currently	  on	  the	  market,	  we	  estimated	  vaccine	  costs	  for	  the	  
Peruvian	  military	  using	  2008	  Pan	  American	  Health	  Organization	  revolving	  fund	  
prices	  for	  Rotarix	  (A.	  D.	  Clark	  et	  al.	  2009;	  “2008	  PAHO	  Revolving	  Fund	  Vaccine	  
Prices”	  2008),	  which	  match	  pre-­‐2016	  GAVI	  pricing	  (“GAVI	  Alliance	  Secures	  Lower	  
Price	  for	  Rotavirus	  Vaccine”	  2012).	  We	  converted	  cost	  estimates	  in	  Peruvian	  
currency	  to	  USD	  using	  an	  exchange	  rate	  of	  0.31	  USD	  per	  Peruvian	  sol.	  	  	  
	  
Outcome	  measures	  and	  sensitivity	  analysis.	  	  We	  selected	  duty	  days	  lost	  (DDL)	  due	  
to	  norovirus-­‐associated	  gastroenteritis	  as	  the	  outcome	  measure.	  The	  cost-­‐
effectiveness	  ratio	  (CER)	  numerator	  was	  the	  cost	  of	  administering	  the	  vaccine	  to	  the	  
Peruvian	  military	  population	  minus	  the	  expected	  care	  costs	  in	  the	  absence	  of	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vaccine	  administration.	  The	  CER	  denominator	  was	  the	  DDL	  averted	  by	  
incorporating	  pathogen-­‐specific	  vaccine	  administration	  into	  the	  Peruvian	  military’s	  
pre-­‐deployment	  vaccine	  program.	  We	  used	  DDL	  estimates	  determined	  by	  a	  
previously	  published	  literature	  review	  and	  data	  collected	  from	  DoD	  surveillance	  
among	  US	  military	  recruits	  seeking	  care	  for	  moderate	  to	  severe	  gastroenteritis	  
(Tallant	  et	  al.	  2014a).	  	  
	   	  
To	  determine	  which	  model	  parameters	  have	  the	  greatest	  impact	  on	  the	  CER	  for	  each	  
pathogen,	  we	  performed	  a	  one-­‐way	  sensitivity	  analysis	  using	  high	  and	  low	  values	  
for	  each	  parameter.	  We	  compared	  the	  resultant	  CERs	  to	  base	  case	  estimates	  to	  
identify	  high-­‐impact	  variables.	  
	  
RESULTS	  
	  We	  present	  the	  base	  case	  results	  in	  Table	  7.	  Implementation	  of	  a	  vaccine	  against	  
Campylobacter,	  ETEC,	  Shigella,	  or	  norovirus	  by	  the	  Peruvian	  military	  would	  
potentially	  prevent	  137,	  2223,	  5902,	  or	  3870	  cases,	  respectively,	  of	  gastroenteritis	  
annually.	  The	  total	  annual	  cost	  of	  the	  program	  would	  be	  $1,447,920	  at	  $15	  per	  
vaccine	  series	  administered.	  Following	  vaccine	  implementation,	  the	  number	  of	  
Campylobacter-­‐,	  ETEC-­‐,	  Shigella-­‐,	  and	  norovirus-­‐associated	  DDL	  is	  projected	  to	  
decrease	  from	  116,	  1201,	  4699,	  and	  1839,	  respectively,	  to	  23,	  240,	  940,	  and	  368,	  
respectively,	  per	  year.	  The	  predicted	  reduction	  in	  total	  annual	  cost	  of	  care	  following	  
vaccine	  introduction	  is	  from	  $3622,	  $58681,	  $155758,	  and	  $102148,	  respectively,	  to	  
$543,	  $8802,	  $23364,	  and	  $15322,	  respectively.	  Based	  on	  the	  input	  parameters	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described,	  pathogen-­‐specific	  vaccine	  implementation	  would	  result	  in	  a	  respective	  
CER	  per	  DDL	  	  (CERDDL),	  or	  cost	  per	  duty	  day	  lost	  averted,	  of	  $15598,	  $1456,	  $350,	  
CEand	  $926,	  and	  a	  respective	  CER	  per	  diarrhea	  day	  averted	  of	  $2418,	  $246,	  $60,	  and	  
$229	  for	  Campylobacter,	  ETEC,	  Shigella,	  and	  norovirus.	  	  
	  
We	  display	  the	  one-­‐way	  sensitivity	  analysis	  results	  in	  tornado	  diagrams	  for	  each	  
pathogen	  (Figure	  4)	  and	  demonstrate	  that	  48-­‐49%	  of	  the	  variation	  in	  the	  economic	  
models	  for	  each	  pathogen	  can	  be	  accounted	  for	  by	  the	  relationship	  between	  
deployment	  duration	  and	  CERDDL.	  For	  all	  four	  pathogens,	  the	  most	  influential	  input	  
parameters	  in	  this	  model	  (in	  order	  of	  importance)	  include:	  deployment	  duration,	  
monthly	  incidence	  of	  pathogen-­‐associated	  disease,	  pathogen	  prevalence,	  vaccine	  
efficacy,	  vaccine	  coverage,	  and	  cost	  per	  dose	  of	  the	  vaccine.	  Together,	  all	  of	  these	  




In	  Peruvian	  military	  populations	  deploying	  to	  the	  Amazon	  Basin,	  vaccines	  against	  
Shigella	  appear	  to	  be	  the	  most	  cost-­‐effective	  in	  preventing	  duty	  days	  lost	  to	  
diarrhea,	  followed	  by	  vaccines	  against	  norovirus,	  ETEC,	  and	  Campylobacter.	  	  
Compared	  to	  estimates	  of	  pathogen-­‐specific	  CERDDL	  for	  vaccines	  implemented	  in	  
military	  populations	  from	  high-­‐income	  countries,	  such	  as	  the	  United	  States,	  Shigella	  
vaccine	  implementation	  is	  significantly	  more	  cost-­‐effective	  for	  the	  Peruvian	  military	  
(CERDDL=$350	  versus	  $1275),	  and	  norovirus	  vaccine	  implementation	  is	  moderately	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more	  cost	  effective	  (CERDDL=$926	  versus	  $1344)	  (Tallant	  et	  al.	  2014a;	  Riddle	  et	  al.	  
2008).	  	  Neither	  Campylobacter	  (CERDDL=	  $15598	  versus	  $800)	  nor	  ETEC	  
(CERDDL=$1456	  versus	  $776)	  vaccine	  implementation	  is	  more	  cost-­‐effective	  in	  the	  
Peruvian	  military	  population	  relative	  to	  that	  of	  the	  United	  States	  (Riddle	  et	  al.	  
2008).	  	  These	  data	  suggest	  that	  future	  vaccine	  acquisition	  strategies	  for	  the	  
Peruvian	  military	  should	  focus	  on	  vaccines	  against	  Shigella	  and	  norovirus.	  	  
	  
Many	  cost-­‐effectiveness	  analyses	  use	  quality	  adjusted	  life	  years	  (QALYs)	  to	  estimate	  
effectiveness.	  However,	  given	  the	  self-­‐limiting	  nature	  of	  most	  acute	  gastroenteritis,	  
we	  deemed	  DDL	  more	  appropriate	  effectiveness	  measure	  than	  QALYs	  because	  it	  
more	  accurately	  represents	  the	  impact	  of	  gastroenteritis	  on	  the	  military	  population	  
and	  can	  be	  better	  understood	  by	  commanders	  and	  medical	  planners.	  	  At	  present,	  no	  
established	  cutoff	  exits	  for	  the	  acceptable	  dollar	  value	  deemed	  to	  be	  cost-­‐effective	  
for	  the	  DDL	  averted	  outcome.	  The	  value	  of	  a	  DDL	  averted	  may	  vary	  based	  on	  the	  
intensity,	  stability,	  and	  location	  of	  operations	  underway	  when	  an	  outbreak	  occurs.	  
In	  the	  United	  States	  military,	  planners	  budget	  an	  operation	  cost	  per	  troop	  of	  
$28,057	  (2012	  dollars)	  per	  month,	  or	  $935	  per	  day	  (Tallant	  et	  al.	  2014a).	  Previous	  
estimates	  have	  exceeded	  this	  at	  $2000-­‐$3000	  per	  troop	  per	  day.	  In	  low-­‐	  and	  middle-­‐
income	  country	  settings,	  this	  value	  is	  likely	  much	  lower,	  although	  not	  well	  
characterized	  in	  the	  literature	  (Tallant	  et	  al.	  2014a).	  Further,	  the	  distraction	  and	  





Estimating	  vaccine	  costs	  for	  military	  populations	  in	  low-­‐	  and	  middle-­‐income	  
countries	  is	  complex.	  Another	  VLP-­‐based	  vaccine,	  human	  papilloma	  virus	  (HPV),	  
from	  PAHO’s	  Revolving	  fund	  and	  from	  a	  study	  in	  Brazil	  (Mirelman	  et	  al.	  2015b)	  
estimates	  the	  vaccine	  cost	  at	  $26.44	  per	  series,	  while	  GAVI	  provides	  vaccination	  for	  
$4.50	  USD	  per	  series.	  However,	  using	  a	  potential	  norovirus	  vaccine	  in	  a	  military	  
population	  may	  eliminate	  the	  opportunity	  for	  the	  Peruvian	  government	  to	  receive	  
subsidized	  pricing	  for	  the	  vaccine,	  which	  may	  be	  exacerbated	  further	  by	  the	  
recategorization	  of	  Peru	  by	  World	  Bank	  as	  an	  upper	  middle-­‐income	  country,	  as	  
opposed	  to	  its	  previous	  designation	  of	  lower	  middle	  income.	  	  	  
	   	  	  	  	  
The	  simplicity	  of	  the	  model	  limited	  our	  evaluation	  of	  several	  factors,	  including	  the	  
potential	  for	  herd	  immunity	  to	  reduce	  or	  significantly	  disrupt	  norovirus	  
transmission	  during	  outbreaks	  and	  residual	  effects	  on	  transmission	  of	  norovirus	  
after	  troops	  return	  to	  garrison	  (ie.	  when	  they	  aren’t	  deployed	  on	  a	  mission).	  
Additionally,	  this	  model	  did	  not	  consider	  the	  potential	  reduction	  in	  chronic	  health	  
sequellae,	  such	  as	  post-­‐infectious	  irritable	  bowel	  syndrome,	  that	  might	  contribute	  to	  
a	  decrease	  in	  future	  medical	  costs	  for	  this	  population.	  
	  
In	  conclusion,	  vaccine	  acquisition	  strategies	  for	  the	  Peruvian	  military	  should	  focus	  
on	  vaccines	  against	  Shigella	  and	  norovirus.	  	  Cost-­‐effectiveness	  ratios	  per	  duty	  day	  
lost	  averted	  should	  be	  further	  defined	  for	  specific	  military	  populations	  and	  
operations	  in	  order	  to	  improve	  decision-­‐making	  for	  operational	  planners.	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IV.	  	  THIRD	  PAPER:	  ETIOLOGY	  OF	  MEDICALLY-­‐ATTENDED	  GASTROENTERITIS	  
IN	  CHILDREN	  YOUNGER	  THAN	  FIVE	  YEARS	  OF	  AGE	  FOLLOWING	  UNIVERSAL	  
ROTAVIRUS	  VACCINE	  IMPLEMENTATION	  IN	  PERU	  
	  
ABSTRACT	  
Future	  pediatric	  gastroenteritis	  control	  strategies	  require	  understanding	  the	  
shifting	  enteropathogen	  landscape	  following	  Rotarix™	  vaccine	  implementation	  in	  
developing	  settings.	  We	  conducted	  this	  case-­‐control	  study	  of	  children	  younger	  than	  
five	  years	  of	  age	  with	  and	  without	  gastroenteritis	  at	  the	  national	  children’s	  hospital	  
in	  Peru	  following	  universal	  Rotarix™	  vaccine	  implementation.	  	  We	  tested	  case	  and	  
control	  stools	  for	  viruses,	  bacteria,	  and	  parasites.	  and	  calculated	  coinfection-­‐
adjusted	  attributable	  fractions	  (AFs)	  to	  determine	  the	  burden	  of	  gastroenteritis	  
attributable	  to	  specific	  pathogens.	  The	  following	  six	  pathogens	  were	  independently	  
positively	  associated	  with	  gastroenteritis:	  norovirus	  GII	  (AF	  29.1,	  95%	  CI:	  28.0-­‐
32.3);	  rotavirus	  (AF	  8.9,	  95%	  CI:	  6.8-­‐9.7);	  	  sapovirus	  (AF	  6.3,	  95%	  CI:	  4.3-­‐7.4);	  ETEC	  
St=/Lt+St+	  (AF	  2.4,	  95%	  CI:	  0.6-­‐3.1);	  Shigella	  (AF	  2.0,	  95%	  CI:	  0.4-­‐2.2);	  and	  
astrovirus	  (AF	  2.8,	  95%	  CI:	  0.0-­‐4.0).	  	  Caliciviruses	  are	  an	  important	  cause	  of	  
diarrhea	  among	  children	  with	  medically-­‐attended	  diarrhea	  in	  Peru.	  Control	  
strategies	  should	  consider	  multivalent	  vaccines	  that	  target	  these	  pathogens.	  
	  
INTRODUCTION	  
Worldwide,	  diarrhea	  is	  a	  leading	  killer	  of	  children	  younger	  than	  five	  years	  of	  age.	  	  
Prior	  to	  the	  introduction	  of	  universal	  national	  vaccination	  programs,	  rotavirus	  was	  
the	  major	  viral	  pathogen	  causing	  diarrhea-­‐associated	  deaths.	  	  In	  countries,	  such	  as	  
Peru,	  where	  Rotarix™	  has	  been	  implemented	  with	  high	  coverage	  rates,	  caliciviruses,	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specifically	  norovirus	  and	  sapovirus,	  have	  emerged	  as	  important	  diarrhea-­‐
associated	  pathogens	  among	  children	  in	  the	  community	  setting.	  	  However,	  little	  is	  
known	  about	  the	  relative	  contribution	  of	  these	  and	  other	  pathogens	  to	  severe	  
diarrhea	  following	  rotavirus	  vaccine	  implementation	  in	  developing	  settings.	  	  	  
	  
We	  conducted	  this	  case	  control	  study	  in	  the	  national	  children’s	  hospital	  in	  Peru	  
following	  the	  universal	  implementation	  of	  a	  vaccine	  against	  rotavirus	  in	  order	  to	  a)	  
determine	  the	  pathogen-­‐specific	  attributable	  risk	  among	  children	  with	  medically-­‐
attended	  gastroenteritis;	  b)	  evaluate	  the	  relationship	  between	  infection	  with	  
specific	  pathogens	  and	  gastroenteritis	  severity;	  and	  c)	  describe	  the	  genetic	  diversity	  
of	  circulating	  norovirus,	  sapovirus,	  and	  rotavirus	  to	  inform	  prevention	  and	  control	  
measures.	  	  	  	  
	  
METHODS	  
Ethics	  statement.	  	  The	  institutional	  review	  boards	  of	  Naval	  Medical	  Research	  Unit	  
No.	  6,	  Instituto	  Nacional	  de	  Salud	  del	  Niño,	  Universidad	  Peruana	  Cayetano	  Heredia,	  
and	  Asociación	  Benéfica	  PRISMA	  approved	  this	  study.	  	  Legal	  authorized	  
representatives	  of	  children	  provided	  written	  informed	  consent	  for	  participation	  at	  
the	  time	  of	  enrollment.	  
	  
Study	  population.	  	  Between	  31	  October	  2013	  and	  31	  May	  2015,	  we	  prospectively	  
enrolled	  children	  younger	  than	  five	  years	  of	  age	  accessing	  care	  at	  the	  national	  
children’s	  hospital	  in	  Lima,	  Peru,	  for	  acute	  gastroenteritis	  (cases)	  or	  reasons	  other	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than	  gastroenteritis	  (hospital-­‐based	  controls).	  We	  recruited	  community-­‐based	  
controls	  from	  an	  ongoing	  cohort	  study	  in	  a	  peri-­‐urban	  shantytown	  in	  southern	  Lima	  
(Saito	  et	  al.	  2014).	  We	  defined	  acute	  gastroenteritis	  as	  the	  onset	  of	  diarrhea	  or	  
vomiting	  within	  three	  days	  of	  enrollment	  (“WHO	  Initiative	  to	  Estimate	  the	  Global	  
Burden	  of	  Foodborne	  Diseases”	  2017).	  We	  defined	  a	  diarrheal	  episode	  by	  the	  
presence	  of	  	  ≥3	  liquid	  or	  semiliquid	  stools	  in	  24	  hours.	  For	  infants	  younger	  than	  2	  
months,	  we	  based	  the	  definition	  on	  the	  caretaker’s	  assessment	  that	  the	  child	  had	  
diarrhea	  (Saito	  et	  al.	  2014).	  An	  episode	  ended	  when	  the	  child	  had	  two	  consecutive	  
days	  without	  diarrhea.	  “Pathogen-­‐associated	  gastroenteritis”	  or	  symptomatic	  
infection	  was	  defined	  as	  positive	  identification	  of	  a	  specific	  pathogen	  in	  a	  stool	  
sample	  collected	  during	  the	  first	  three	  days	  of	  the	  gastroenteritis	  episode.	  
“Asymptomatic”	  infection	  occurred	  when	  no	  symptoms	  were	  reported	  within	  seven	  
days	  of	  the	  positive	  specimen	  collected	  at	  the	  time	  of	  enrollment.	  	  Exclusion	  criteria	  
were:	  hospitalization	  for	  ≥1	  month	  at	  birth,	  any	  congenital	  defect,	  birth	  weight	  
<1500	  g,	  and	  a	  diarrhea	  episode	  within	  the	  30	  days	  preceding	  enrollment.	  	  At	  the	  
time	  of	  enrollment,	  a	  trained	  healthcare	  provider	  administered	  a	  survey	  to	  assess	  
each	  participant’s	  demographics,	  socioeconomic	  status,	  and	  history	  of	  present	  
illness.	  	  Study	  nurses	  collected	  the	  participant’s	  anthropometric	  data,	  and	  a	  study	  
physician	  conducted	  a	  clinical	  examination	  before	  collecting	  serum,	  stool	  (whole	  
stool	  or	  rectal	  swab),	  and	  saliva	  samples.	  	  After	  enrollment,	  a	  study	  nurse	  called	  
each	  participant’s	  caregiver	  daily	  to	  prospectively	  collect	  information	  about	  the	  
clinical	  features	  of	  illness,	  health-­‐related	  behaviors,	  and	  costs	  related	  to	  the	  illness.	  	  
 
	  44	  
These	  daily	  follow	  up	  phone	  calls	  continued	  until	  the	  caregiver	  reported	  that	  the	  
participant	  was	  asymptomatic	  for	  48	  hours.	  	  	  
	  
Calicivirus	  detection	  and	  genotyping.	  A	  suspension	  of	  each	  stool	  specimen	  (10%	  
wt/vol),	  stored	  at	  -­‐80	  °C,	  prepared	  in	  phosphate	  buffered	  saline,	  was	  allowed	  to	  
thaw	  at	  4	  °C,	  and	  RNA	  was	  extracted	  using	  the	  Qiagen	  QIAmp	  viral	  RNA	  kit	  
(Valencia,	  CA)	  in	  accordance	  with	  the	  manufacturer’s	  instructions.	  Viral	  RNA	  was	  
tested	  for	  norovirus	  GI	  and	  GII	  by	  real-­‐time	  polymerase	  chain	  reaction	  (PCR)	  (Apaza	  
et	  al.	  2012).	  A	  sample	  was	  considered	  positive	  if	  the	  negative	  control	  did	  not	  exhibit	  
fluorescent	  curves.	  The	  threshold	  cycle	  for	  the	  sample	  was	  at	  least	  37	  for	  norovirus	  
GI	  and	  39	  for	  GII.	  Positive	  samples	  were	  then	  genotyped	  by	  sequencing	  Region	  C	  
within	  the	  capsid	  gene	  after	  conventional	  PCR	  and	  gel-­‐purification	  of	  amplicons,	  
comparing	  results	  with	  norovirus	  prototypic	  strains	  using	  the	  NoroNet	  sequence	  
typing	  tool	  (Kroneman	  et	  al.	  2011).	  	  We	  detected	  and	  genotyped	  sapovirus	  as	  
described	  in	  (X.	  Liu	  et	  al.	  2016).	  Aichi	  virus	  and	  astrovirus	  were	  identified	  on	  a	  
randomly	  selected	  subset	  of	  children	  using	  conventional	  methods	  (Chuchaona	  et	  al.	  
2017;	  Lopez	  et	  al.	  2017).	  	  	  
	  
Rotavirus	  detection	  and	  genotyping.	  	  To	  identify	  rotavirus-­‐positive	  samples,	  we	  
conducted	  qRT-­‐PCR	  on	  the	  diluted	  the	  thawed	  stool	  specimen	  suspensions,	  
targeting	  an	  87	  bp	  fragment	  of	  the	  highly	  conserved	  NSP3	  region	  of	  rotavirus	  group	  
A	  using	  previously	  described	  primers	  and	  protocols	  from	  the	  Centers	  for	  Disease	  
Control	  and	  Prevention,	  Atlanta,	  GA	  (Freeman	  et	  al.	  2008).	  	  We	  genotyped	  all	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rotavirus	  positive	  samples	  using	  a	  semi-­‐nested	  RT-­‐PCR	  to	  identify	  VP7	  (G)	  and	  VP4	  
(P)	  genotypes	  as	  described	  previously	  (Gouvea	  et	  al.	  1990;	  Gouvea	  and	  Santos	  1999;	  
Das	  et	  al.	  1994).	  	  	  	  
	  
Bacteria	  and	  parasite	  identification.	  At	  the	  time	  of	  collection,	  fresh	  stool	  
specimens	  were	  transported	  in	  Cary-­‐Blair	  medium	  and	  wide-­‐mouthed	  containers	  to	  
the	  NAMRU-­‐6	  laboratory	  in	  Iquitos	  for	  bacteria	  and	  parasite	  analysis,	  respectively.	  
Escherichia	  coli	  and	  Salmonella,	  Shigella,	  Yersinia,	  and	  Campylobacter	  spp.	  were	  
cultured	  and	  isolated	  as	  previously	  described	  (Gray	  1995;	  Nachamkin	  1999).	  
Polymerase	  chain	  reaction	  for	  heat	  labile	  and	  stable	  enterotoxigenic	  E.	  coli	  (ETEC),	  
diffuse-­‐adhering	  E.	  coli	  (DAEC),	  enteroaggregative	  E.	  coli	  (EAEC),	  enteropathogenic	  
E.	  coli	  (EPEC),	  enteroinvasive	  E.	  coli	  (EIEC),	  and	  Shigatoxin	  1-­‐	  and	  Shigatoxin	  2-­‐
producing	  shigatoxigenic	  E.	  coli	  (STX1/STX2	  STEC)	  was	  performed	  on	  five	  lactose-­‐
fermenting	  colonies	  morphologically	  resembling	  E.	  coli	  (Stacy-­‐Phipps,	  Mecca,	  and	  
Weiss	  1995).	  Plesiomonas	  spp.	  were	  identified	  using	  the	  method	  of	  Hugh	  (Hugh	  
1970).	  Vibrio	  cholerae	  were	  isolated	  using	  thiosulfate	  citrate	  bile	  salts	  sucrose	  agar	  
(Laboratory	  Methods	  for	  the	  Diagnosis	  of	  Vibrio	  Cholerae:	  Isolation	  of	  Vibrio	  Cholerae	  
from	  Fecal	  Specimens	  2016).	  Microscopy	  for	  ova	  and	  parasites	  was	  performed	  on	  
saline	  wet	  preparations	  to	  detect	  protozoa	  and	  helminth	  infections.	  We	  used	  the	  





Statistical	  methods.	  Statisical	  analysis	  was	  performed	  using	  Stata	  version	  13.0	  
(StataCorp	  LP,	  College	  Station,	  TX).	  	  By	  convention,	  P	  values	  less	  than	  0.05	  were	  
considered	  statistically	  significant.	  	  Exploratory	  analysis	  of	  participant	  
demographics,	  diarrhea	  risk	  factors,	  and	  clinical	  features	  of	  illness	  was	  performed,	  
and	  child	  growth	  parameters	  were	  calculated	  using	  the	  World	  Health	  Organization	  
standards	  (De	  Onis	  et	  al.	  2017).	  	  The	  2-­‐tailed	  Student	  t	  test	  was	  used	  for	  comparison	  
of	  continuous	  outcome	  variable	  means.	  Proportions	  were	  compared	  using	  Fisher’s	  
exact	  test.	  	  
	  
The	  statistical	  analysis	  for	  predictors	  of	  diarrhea	  was	  performed	  in	  several	  steps;	  
first,	  the	  association	  of	  diarrhea	  with	  specific	  pathogens	  was	  evaluated	  using	  simple	  
and	  multiple	  logistic	  regression	  analyses.	  Variance	  inflation	  factors	  were	  all	  below	  
zero.	  Forward	  and	  backward	  stepwise	  selection	  was	  used	  to	  select	  variables	  for	  
regression	  models.	  Nested	  models	  were	  compared	  using	  Akaike’s	  Information	  
Criteria.	  Potential	  interactions	  were	  evaluated	  with	  regression	  models.	  We	  
performed	  sensitivity	  analyses	  to	  evaluate	  the	  relationship	  between	  viral	  infections	  
and	  gastroenteritis	  by	  recategorizing	  virus-­‐bacteria	  coinfected	  children	  as	  positive	  
for	  only	  the	  coinfecting	  bacteria	  and	  reevaluating	  the	  relationship	  between	  specific	  
viruses	  and	  gastroenteritis	  using	  the	  logistic	  regression	  analysis	  described	  above.	  	  
We	  used	  adjusted	  odds	  ratios	  and	  pathogen	  prevalence	  among	  cases	  to	  calculate	  
adjusted	  population	  attributable	  fractions	  (AFs)	  to	  estimate	  the	  pathogen-­‐specific	  
disease	  burden	  (Bruzzi	  et	  al.	  1985).	  The	  adjusted	  AF	  is	  derived	  from	  the	  logistic	  
regression	  model	  that	  includes	  other	  pathogens	  significantly	  associated	  with	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diarrhea;	  thus,	  it	  is	  the	  AF	  adjusted	  for	  the	  presence	  of	  other	  pathogens.	  Diarrhea	  
was	  considered	  to	  be	  attributable	  to	  the	  pathogen	  identified	  in	  stools	  collected	  at	  
the	  time	  of	  a	  diarrhea	  episode.	  	  	  	  	  	  	  
	  
RESULTS	  
Participant	  characteristics	  (Table	  8).	  	  During	  the	  18-­‐month	  study	  period,	  we	  
enrolled	  1,788	  participants	  (57%	  male)	  in	  the	  study:	  932	  medically-­‐attended	  
children	  with	  gastroenteritis	  and	  856	  controls	  without	  gastroenteritis.	  	  Of	  the	  cases,	  
666	  had	  both	  diarrhea	  and	  vomiting,	  and	  164	  had	  only	  diarrhea,	  and	  102	  had	  only	  
vomiting.	  	  Of	  the	  controls,	  400	  were	  hospital-­‐based,	  and	  456	  were	  community-­‐
based.	  	  Relative	  to	  controls,	  case	  enrollment	  was	  significantly	  higher	  from	  December	  
through	  May.	  Cases	  scored	  significantly	  higher	  than	  controls	  on	  the	  modified	  PPI	  
scale	  (39	  v.	  32)	  and	  were	  significantly	  more	  likely	  than	  controls	  to	  have	  improved	  
sanitation	  (94%	  v.	  40%)	  and	  water	  sources	  (90%	  v.	  41%)	  at	  home.	  	  Cases	  and	  
controls	  had	  similar	  blood	  group	  and	  Rhesis	  factor	  prevalences.	  	  Cases	  had	  
significantly	  higher	  first	  (97%	  v.	  92%)	  and	  second	  (92%	  v.	  85%)	  Rotarix™	  
immunization	  rates	  relative	  to	  controls.	  	  Cases	  had	  significantly	  lower	  length-­‐for-­‐age	  
(0.05	  [SD	  2.28]	  v.	  0.31	  [SD	  1.81]_	  and	  weight-­‐for-­‐age	  90.11	  [SD	  1.28]	  v.	  0.53	  [SD	  
1.23])	  z	  scores	  relative	  to	  controls,	  in	  addition	  to	  having	  lower	  hematocrit	  levels	  
relative	  to	  controls	  (35.0	  v.	  35.5).	  
	  
Pathogen-­‐specific	  gastroenteritis	  disease	  burden	  (Table	  8,	  9).	  	  We	  identified	  at	  
least	  one	  organism	  in	  73%	  of	  case	  stools	  and	  44%	  of	  control	  stools.	  	  Among	  case	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stools,	  we	  identified	  viruses	  in	  57%,	  bacteria	  in	  39%,	  and	  parasites	  in	  5%.	  	  Among	  
control	  stools,	  we	  identified	  viruses	  in	  21%,	  bacteria	  in	  26%,	  and	  parasites	  in	  15%.	  	  
We	  identified	  two	  or	  more	  organisms	  in	  34%	  of	  cases	  (215	  cases	  had	  two,	  48	  had	  
three,	  5	  had	  four,	  and	  2	  had	  five),	  and	  4%	  of	  controls	  (32	  had	  two,	  and	  one	  had	  four).	  	  
The	  most	  prevalent	  viruses	  and	  bacteria	  among	  cases	  were:	  norovirus	  (36%),	  DAEC	  
(16%),	  rotavirus	  (11%),	  sapovirus	  (8%),	  EAEC	  (7%),	  ETEC	  (5%),	  astrovirus	  (5%),	  
EPEC	  (5%),	  Campylobacter	  sp.	  (3%),	  Aeromonas	  (3%),	  Shigella	  sp.	  (2%),	  Salmonella	  
(2%),	  and	  STEC	  (1%).	  	  Among	  controls,	  the	  most	  prevalent	  were:	  DAEC	  (13%),	  
norovirus	  (12%),	  EPEC	  (4%),	  EAEC	  (4%),	  rotavirus	  (3%),	  sapovirus	  (3%),	  
astrovirus	  (3%),	  ETEC	  (3%),	  Salmonella	  (2%),	  Aeromonas	  (2%),	  and	  Campylobacter	  
sp.	  (2%).	  	  The	  remaining	  pathogens	  were	  absent	  or	  less	  than	  1%	  prevalent.	  	  The	  
most	  prevalent	  parasites	  among	  cases	  were	  Giardia	  (3%),	  Cyclospora	  (0.9%),	  
Entamoeba	  coli	  (0.7%),	  Chilomastix	  mesnili	  (0.7%).	  	  The	  most	  prevalent	  among	  
controls	  were	  Giardia	  (9%),	  Entamoeba	  coli	  (5%),	  Endolimax	  nana	  (2%),	  Chilomastix	  
mesnili	  (1%),	  and	  Cryptosporidium	  (0.6%).	  	  The	  remaining	  pathogens	  were	  absent	  
or	  less	  than	  0.5%	  prevalent.	  	  	  	  	  	  	  	  
	  
Relative	  to	  those	  of	  controls,	  stools	  from	  children	  with	  gastroenteritis	  had	  a	  
significantly	  higher	  prevalence	  of	  norovirus	  (36%	  v.	  12%,	  pathogenicity	  index	  
[PI]=2.9),	  rotavirus	  (11%	  v.	  3%,	  PI=3.1),	  sapovirus	  (8%	  v.	  3%,	  PI=2.8),	  EAEC	  (7%	  v.	  
4%,	  PI=1.9),	  ETEC	  (5%	  v.	  3%,	  PI=2.0),	  astrovirus	  (5%	  v.	  3%,	  PI=2.9),	  Campylobacter	  
sp.	  (3%	  v.	  2%,	  PI=1.9),	  and	  Shigella	  sp.	  (2%	  v.	  0.2%,	  PI=8.9).	  	  Relative	  to	  those	  of	  





Norovirus	  and	  sapovirus	  genogroup/genotype	  relationship	  with	  diarrhea.	  	  We	  
successfully	  genotyped	  282/337	  (84%)	  of	  norovirus	  and	  65/71	  (92%)	  of	  sapovirus	  
isolated	  from	  children	  with	  gastroenteritis;	  31/32	  (66%)	  of	  norovirus	  and	  6/6	  
(100%)	  of	  sapovirus	  from	  asymptomatic	  hospital-­‐based	  controls;	  and	  51/74	  (67%)	  
of	  norovirus	  and	  11/20	  (55%)	  of	  sapovirus	  from	  asymptomatic	  community-­‐based	  
controls.	  	  The	  most	  frequently	  observed	  norovirus	  genotype	  was	  GII.4	  (68%),	  
followed	  by	  GII.6	  (10%),	  and	  GII.17	  (9%).	  	  Between	  the	  two	  norovirus	  genogroups,	  
we	  found	  GII	  more	  frequently	  in	  gastroenteritis-­‐associated	  infections	  than	  in	  
asymptomatic	  controls	  (33%	  v.	  9%,	  P<0.01).	  	  GI	  was	  found	  in	  3%	  children	  with	  
gastroenteritis	  and	  4%	  of	  asymptomatic	  controls	  (P=0.69).	  	  Among	  those	  with	  
genotype	  information,	  norovirus	  genotypes	  GI.1,	  GI.3,	  GI.5,	  GII.4,	  GII.6,	  GII.12,	  GII.14,	  
GII.23	  were	  significantly	  more	  frequent	  in	  children	  with	  gastroenteritis.	  	  We	  
identified	  norovirus	  GII.8	  and	  GII.13	  only	  in	  asymptomatic	  controls.	  	  	  
	  
Of	  the	  four	  genogroups	  of	  sapovirus,	  we	  most	  frequently	  observed	  GI	  (49%),	  
followed	  by	  GII	  (30%),	  GIV	  (11%),	  and	  GIV	  (10%).	  	  Among	  those	  with	  genotype	  
information,	  65	  were	  gastroenteritis-­‐associated,	  and	  16	  were	  associated	  with	  
asymptomatic	  controls	  from	  the	  community	  or	  hospital	  settings.	  	  Among	  the	  four	  
genogroups,	  we	  found	  GI,	  GII,	  GIV,	  and	  GV	  more	  frequently	  in	  children	  with	  
gastroenteritis	  (4%,	  2%,	  1%,	  1%,	  respectively)	  than	  in	  asymptomatic	  children	  (1%,	  
0.5%,	  0.4%,	  0.2%,	  respectively).	  When	  analyzed	  by	  genotype,	  12	  of	  the	  19	  known	  
genotypes	  were	  identified.	  	  Within	  these	  12	  genotypes,	  we	  most	  frequently	  
identified	  GI/2	  (32%),	  followed	  by	  GI/1	  (15%),	  GII/4	  (17%),	  GIV/1	  (9%)	  and	  GV/1	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(9%).	  Genotypes	  GI/1,	  GI/2,	  GI/3,	  GI/5,	  GII/1,	  GII/2,	  GII/4,	  GII/5,	  GII/8,	  GIV/1,	  and	  
GV/1	  were	  more	  frequent	  in	  children	  with	  gastroenteritis	  than	  asymptomatic	  
controls.	  	  Within	  the	  12	  genotypes	  identified,	  we	  only	  detected	  genotype	  GI/6	  more	  
frequently	  in	  asymptomatic	  controls	  compared	  with	  gastroenteritis	  cases,	  but	  this	  
difference	  was	  not	  statistically	  significant.	  	  
	  
Rotavirus	  genotype	  relation	  to	  diarrhea,	  vaccination	  status,	  and	  disease	  
severity.	  	  Rotavirus	  infections	  peaked	  from	  July	  through	  December,	  which	  
correspond	  with	  the	  colder	  months	  in	  Lima	  (Figure	  5).	  	  Of	  the	  127	  rotavirus-­‐positive	  
samples	  (98	  cases,	  28	  controls),	  81	  (64%)	  had	  typable	  G	  and	  P	  types.	  	  Among	  cases	  
with	  typable	  rotavirus,	  we	  most	  frequently	  identified	  the	  heterotypic	  strain	  G12P[8]	  
(54/81,	  67%).	  	  Of	  the	  54	  children	  with	  G12P[8]-­‐associated	  gastroenteritis,	  48	  (89%)	  
had	  received	  Rotarix™	  dose	  one,	  and	  45	  (83%)	  had	  received	  Rotarix™	  dose	  two.	  	  
Among	  the	  9	  children	  (2	  cases,	  7	  controls)	  infected	  with	  G1P[8],	  the	  vaccine	  strain	  of	  
rotavirus,	  	  8	  (2	  cases,	  6	  controls)	  had	  received	  one	  dose,	  and	  4	  (2	  cases,	  2	  controls)	  
had	  received	  two	  doses	  of	  Rotarix™.	  	  Having	  received	  one	  dose	  of	  Rotarix™	  did	  not	  
significantly	  impact	  the	  severity	  of	  diarrhea	  among	  children	  with	  rotavirus-­‐
associated	  gastroenteritis	  compared	  with	  their	  unimmunized	  children	  (median	  
Vesikari	  score	  12.5	  v.	  13	  [both	  moderate];	  median	  Clark	  score	  11.5	  v.	  12.5	  [both	  
severe],	  respectively),	  although	  both	  scales	  revealed	  a	  0.5	  point	  trend	  toward	  
increased	  severity	  among	  unimmunized	  children.	  	  Having	  received	  two	  doses	  of	  
Rotarix™	  did	  not	  significantly	  impact	  the	  severity	  of	  diarrhea	  among	  children	  with	  
rotavirus-­‐associated	  gastroenteritis	  compared	  with	  their	  unimmunized	  children	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(median	  Vesikari	  score	  12	  v.	  13	  [both	  “moderate”];	  median	  Clark	  score	  11	  v.	  12	  
[both	  “severe”],	  respectively),	  although	  both	  scales	  revealed	  a	  one	  point	  trend	  
toward	  increased	  severity	  among	  unimmunized	  children.	  
	  
DISCUSSION	  
Using	  a	  comprehensive	  panel	  of	  microbiological	  assays,	  we	  performed	  this	  hospital-­‐
based	  case-­‐control	  study	  to	  better	  characterize	  the	  etiology	  of	  medically-­‐attended	  
gastroenteritis	  in	  a	  developing	  setting	  following	  the	  implementation	  of	  a	  universal	  
vaccine	  against	  rotavirus.	  	  By	  including	  asymptomatic	  control	  children	  without	  
gastroenteritis,	  we	  derived	  burden	  estimates	  adjusted	  for	  the	  occurrence	  of	  
asymptomatic	  enteropathogens	  often	  seen	  in	  children	  living	  in	  fecally	  contaminated	  
environments,	  and	  derived	  an	  AF	  for	  every	  pathogen	  that	  was	  independently	  
associated	  with	  medically-­‐attended	  gastroenteritis	  in	  regression	  models,	  adjusting	  
for	  interactions	  and	  confounding	  effects	  of	  coinfecting	  enteropathogens.	  	  These	  
pathogen-­‐specific	  adjusted	  AFs	  estimate	  the	  proportion	  of	  medically-­‐attended	  
gastroenteritis	  that	  could	  be	  prevented	  with	  targeted	  interventions	  such	  as	  effective	  
vaccines.	  	  We	  further	  described	  the	  genetic	  epidemiology	  of	  the	  three	  most	  
frequently	  identified	  viral	  pathogens,	  norovirus,	  rotavirus,	  and	  sapovirus,	  in	  order	  
to	  inform	  these	  control	  measures.	  
	  
This	  study	  revealed	  several	  noteworthy	  findings	  about	  young	  children	  with	  
medically-­‐attended	  gastroenteritis.	  	  First,	  despite	  our	  detection	  of	  a	  wide	  variety	  of	  
viruses,	  bacteria,	  and	  parasites	  in	  the	  stools	  of	  young	  children	  in	  this	  setting,	  a	  small	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number	  contributed	  to	  the	  majority	  of	  gastroenteritis	  cases,	  most	  notably	  norovirus	  
GII,	  rotavirus,	  sapovirus,	  and	  astrovirus.	  	  The	  combined	  burden	  of	  gastroenteritis	  
attributable	  to	  these	  four	  viruses	  is	  53.4%.	  	  The	  only	  bacteria	  independently	  
associated	  with	  gastroenteritis	  in	  this	  population,	  Shigella	  	  and	  St+	  producing	  ETEC,	  
had	  a	  combined	  attributable	  fraction	  of	  only	  5.3%.	  	  Other	  organisms,	  such	  as	  
Campylobacter	  spp.,	  Cryptosporidium,	  Aeromonas,	  and	  Vibrio	  cholerae	  O1,	  which	  
have	  been	  associated	  with	  moderate-­‐to-­‐severe	  diarrhea	  in	  multi-­‐center	  studies	  
conducted	  in	  Africa	  and	  Asia	  (Kotloff	  et	  al.	  2013),	  were	  remarkably	  absent	  (in	  the	  
case	  of	  cholera)	  or	  not	  associated	  with	  gastroenteritis	  in	  this	  hospital-­‐based	  South	  
American	  population.	  	  These	  differences	  in	  circulating	  pathogens	  could	  be	  due	  to	  
population	  differences	  in	  nutritional	  status	  or	  medical	  comorbidities,	  in	  addition	  to	  
differences	  in	  the	  study	  design,	  definition	  gastroenteritis,	  and	  measures	  of	  disease	  
severity	  (Ballard,	  Saito,	  et	  al.	  2015b).	  Neither	  our	  study	  nor	  the	  Global	  Enterics	  
Multicenter	  Study	  (GEMS)	  found	  an	  association	  between	  EPEC	  and	  acute	  
gastroenteritis,	  despite	  the	  known	  causal	  relationship	  between	  typical	  EPEC	  
infection	  and	  diarrhea	  (M	  M	  Levine	  et	  al.	  1978).	  	  However,	  we	  did	  not	  conduct	  
studies	  to	  determine	  whether	  our	  EPEC	  isolates	  represented	  typical	  or	  atypical	  
strains,	  which	  demonstrated	  different	  virulence	  characteristics	  (Trabulsi,	  Keller,	  
and	  Gomes	  2002).	  	  Interestingly,	  co-­‐infection	  with	  any	  parasite	  was	  associated	  with	  
a	  decreased	  risk	  of	  gastroenteritis.	  Similar	  to	  adults	  from	  endemic	  settings	  in	  whom	  
Trichuris	  infection	  appears	  protective	  for	  gastroenteritis	  (Ballard,	  Reaves,	  et	  al.	  
2015b),	  we	  speculate	  that	  parasitic	  infection	  in	  our	  population	  serves	  as	  a	  proxy	  for	  
frequent	  previous	  infection	  and	  consequent	  enhanced	  immunity	  to	  enteric	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pathogens.	  	  Alternately,	  this	  could	  represent	  a	  measurement	  bias	  as	  a	  result	  of	  
dilution	  of	  stool	  and	  the	  subsequent	  decreased	  parasite	  detection	  sensitivity	  could	  
occur	  during	  watery	  diarrheal	  episodes.	  
	  	  
Defining	  gastroenteritis	  disease	  severity	  is	  notoriously	  difficult,	  and	  results	  in	  the	  
inability	  to	  accurately	  compare	  results	  across	  studies.	  	  Here,	  we	  prospectively	  
collected	  information	  about	  the	  clinical	  features	  of	  disease	  in	  children	  presenting	  
with	  gastroenteritis.	  	  We	  demonstrated	  large	  discrepancies	  between	  the	  modified	  
20-­‐point	  Vesikari	  and	  24-­‐point	  Clark	  scale	  in	  regard	  to	  the	  definition	  of	  severe	  
diarrhea.	  	  Despite	  these	  differences,	  both	  scales	  demonstrated	  a	  significantly	  higher	  
gastroenteritis	  severity	  in	  children	  with	  norovirus	  GII	  positive	  v.	  GII	  negative	  
gastroenteritis	  episodes,	  and	  episodes	  in	  children	  aged	  6-­‐12	  months	  versus	  other	  
ages.	  	  The	  primary	  concern	  related	  to	  discrepancies	  in	  definitions	  of	  severe	  
gastroenteritis	  is	  with	  regard	  to	  their	  use	  in	  disease	  burden	  estimates	  and	  
intervention	  efficacy	  studies.	  	  The	  GEMS	  study,	  which	  was	  the	  pivotal	  study	  
evaluating	  diarrhea	  disease	  burdens	  across	  Africa	  and	  Asia,	  employed	  different	  
definitions	  of	  both	  diarrhea	  and	  “moderate-­‐to-­‐severe”	  disease.	  	  As	  discussed	  
elsewhere	  (Ballard,	  Saito,	  et	  al.	  2015b),	  the	  reliance	  of	  this	  study	  on	  the	  WHO	  
definition	  of	  diarrhea,	  and	  its	  failure	  to	  include	  children	  with	  vomiting-­‐only	  
gastroenteritis	  episodes,	  likely	  biased	  the	  study	  toward	  a	  lower	  norovirus-­‐
attributable	  fraction	  of	  disease.	  	  Likewise,	  GEMS	  did	  not	  prospectively	  evaluate	  
diarrhea	  severity	  or	  use	  an	  accepted	  severity	  scoring	  system,	  such	  as	  the	  Vesikari	  or	  
Clark	  scales.	  	  Rather,	  it	  evaluated	  severity	  at	  a	  single	  point	  during	  the	  episode	  and	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categorized	  it	  as	  “moderate-­‐to-­‐severe”	  if	  the	  child	  had	  at	  least	  one	  of	  the	  following	  at	  
the	  time	  of	  evaluation:	  sunken	  eyes,	  loss	  of	  skin	  turgor,	  visible	  blood	  in	  loose	  stools,	  
utilization	  of	  intravenous	  hydration,	  or	  hospital	  admission	  for	  diarrhea	  or	  dysentery	  
(Kotloff	  et	  al.	  2013).	  	  The	  dysentery-­‐focus	  of	  these	  severity	  criteria	  increases	  the	  
likelihood	  of	  enrolling	  cases	  with	  bacterial	  rather	  than	  viral	  gastroenteritis	  
etiologies.	  
	  
Following	  the	  implementation	  of	  pediatric	  vaccines	  against	  rotavirus	  in	  Peru,	  
norovirus	  GII	  has	  emerged	  as	  the	  enteropathogen	  with	  the	  highest	  AF	  (29%)	  of	  all	  
pathogens	  identified	  in	  this	  study.	  	  Relative	  to	  children	  with	  non-­‐norovirus-­‐
associated	  gastroenteritis,	  children	  with	  norovirus-­‐associated	  gastroenteritis	  
demonstrated	  a	  higher	  mean	  severity	  score	  on	  both	  the	  Vesikari	  and	  Clark	  severity	  
scales.	  	  Individuals	  with	  norovirus	  GII-­‐associated	  gastroenteritis	  consistently	  
demonstrate	  more	  severe	  clinical	  features	  relative	  to	  individuals	  with	  norovirus	  GI-­‐
associated	  gastroenteritis	  (Ballard,	  Reaves,	  et	  al.	  2015a).	  	  However,	  there	  are	  
increasing	  reports	  of	  norovirus	  causing	  severe	  disease,	  especially	  in	  
immunologically	  naïve	  individuals,	  such	  as	  travelers	  to	  Cusco,	  Peru,	  91%	  of	  whom	  
were	  confined	  to	  bed	  during	  norovirus-­‐associated	  gastroenteritis	  episodes	  
(Jennings,	  Tilley,	  Ballard,	  Villanueva,	  Costa,	  Lopez,	  Steinberg,	  Luna,	  et	  al.	  2017).	  	  Our	  
finding	  that	  6-­‐12	  month	  old	  infants	  experience	  more	  severe	  disease	  serves	  supports	  
this,	  since	  maternal	  antibodies	  have	  waned	  by	  this	  age	  and	  weaning	  increases	  the	  
risk	  of	  diarrhea	  among	  young	  children	  (Santos	  et	  al.	  2015).	  	  In	  order	  to	  prevent	  
severe	  disease,	  vaccines	  against	  norovirus	  must	  target	  circulating	  norovirus	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genotypes	  and	  variants	  (Saito	  et	  al.	  2014).	  	  This	  is	  challenging	  because	  circulating	  
strains	  of	  norovirus	  are	  genetically	  diverse,	  as	  demonstrated	  by	  our	  identification	  of	  
12	  different	  genotypes	  among	  hospital	  cases.	  Nevertheless,	  the	  GII.4	  genotype	  
predominated	  overwhelmingly,	  followed	  by	  temporally	  clustered	  GII.17	  and	  GII.6	  
cases,	  suggesting	  that,	  similar	  to	  the	  influenza	  vaccine	  model,	  surveillance	  systems	  
could	  be	  useful	  in	  informing	  vaccine	  development.	  	  	  	  	  	  
	  	  	  	  
In	  our	  hospital	  population	  with	  gastroenteritis,	  sapovirus	  was	  only	  slightly	  less	  
genetically	  diverse	  compared	  with	  community	  setting,	  where	  all	  four	  human	  
sapovirus	  genotypes	  and	  14	  of	  the	  19	  known	  genotypes	  affecting	  humans	  were	  
recently	  identified	  (G.	  J.	  Sanchez	  et	  al.	  2017).	  	  Among	  our	  hospital	  cases,	  the	  genetic	  
diversity	  (consisting	  of	  all	  four	  genogroups	  and	  12	  genotypes)	  of	  sapovirus	  is	  more	  
diverse	  when	  compared	  to	  other	  developing	  and	  developed	  hospital	  settings.	  	  Only	  
sapovirus	  GI	  was	  detected	  in	  Vietnam	  and	  Bangladesh	  (Hansman	  et	  al.	  2004;	  Shuvra	  
Kanti	  Dey	  et	  al.	  2007),	  and	  only	  sapovirus	  GI	  and	  GII	  were	  reported	  in	  a	  U.S.	  study	  
(Chhabra	  et	  al.	  2013).	  	  In	  Japan	  (S	  K	  Dey	  et	  al.	  2012)	  and	  the	  Philippines	  (X.	  Liu	  et	  al.	  
2015),	  sapovirus	  GV	  and	  GIV,	  respectively,	  were	  not	  reported.	  	  We	  detected	  
sapovirus	  GI	  more	  frequently	  than	  GII	  (50%	  v.	  31%),	  similar	  to	  the	  findings	  of	  a	  
community-­‐based	  study	  in	  Nicaragua	  (Bucardo	  et	  al.	  2014).	  For	  unknown	  reasons,	  
sapovirus	  GI	  may	  be	  more	  pathogenic,	  as	  it	  is	  frequently	  detected	  in	  diarrhea	  





The	  diversity	  of	  circulating	  rotavirus	  strains	  in	  Peru	  has	  not	  been	  well	  characterized	  
since	  the	  2009	  introduction	  of	  vaccines	  rotavirus	  to	  the	  childhood	  immunization	  
schedule	  in	  Peru.	  	  In	  this	  population	  of	  young	  children	  exposed	  to	  the	  universal	  
Rotarix™	  vaccination	  program,	  we	  noted	  a	  predominance	  of	  G12P[8]	  in	  this	  
population.	  	  Since	  1998,	  the	  G12	  genotype	  has	  been	  isolated	  in	  Asia,	  Europe,	  and	  the	  
Americas,	  suggesting	  global	  expansion	  and	  propagation	  of	  this	  strain	  (Rahman	  et	  al.	  
2007;	  Soares	  et	  al.	  2012).	  	  G12	  has	  been	  previously	  reported	  in	  Latin	  American	  
countries,	  including	  Brazil	  and	  Argentina,	  associated	  with	  P[6],	  and	  P[9],	  	  (Rahman	  
et	  al.	  2007;	  Pietruchinski	  et	  al.	  2006;	  Castello	  et	  al.	  2009;	  Stupka	  et	  al.	  2012;	  Soares	  
et	  al.	  2012).	  	  In	  one	  Spanish	  study,	  G12	  was	  most	  commonly	  associated	  with	  P[8],	  
similar	  to	  our	  findings	  (Cilla	  et	  al.	  2010).	  A	  recent	  outbreak	  of	  G12P[8]-­‐associated	  
gastroenteritis	  among	  adults	  in	  the	  United	  States	  provides	  additional	  evidence	  of	  
the	  pathogenic	  importance	  of	  this	  emergent	  strain	  (Pacilli	  et	  al.	  2015).	  The	  Rotarix™	  
vaccine	  used	  throughout	  Latin	  America	  and	  the	  developing	  world	  is	  not	  composed	  
of	  a	  G12	  reassortant	  rotavirus,	  and	  vaccine	  efficacy	  against	  this	  strain	  is	  not	  yet	  
known.	  	  However,	  RotaTeq™	  appears	  to	  have	  an	  approximate	  efficacy	  of	  80%	  
against	  G12	  (D.	  C.	  Payne	  et	  al.	  2013).	  	  This	  suggests	  that	  the	  use	  of	  RotaTeq™	  and	  
similar	  vaccines	  with	  G12	  coverage	  may	  be	  necessary	  to	  control	  rotavirus	  in	  the	  
future.	  	  	  	  
	  
Limitations	  of	  the	  study	  include	  the	  endemicity	  of	  many	  enteropathogens	  in	  the	  
study	  population,	  creating	  and	  environment	  in	  which	  the	  same	  organism	  are	  
detected	  in	  cases	  and	  controls,	  which	  could	  result	  in	  an	  underestimation	  of	  the	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contribution	  of	  specific	  pathogens	  to	  the	  burden	  of	  medically-­‐attended	  
gastroenteritis.	  	  Calicivirus	  genotyping	  limitations	  include	  the	  inability	  to	  genotype	  
all	  of	  the	  norovirus	  and	  sapovirus	  speciments.	  	  In	  addition,	  norovirus	  and	  sapovirus	  
genotyping	  was	  based	  on	  partial	  sequencing	  of	  the	  VP2	  and	  VP1	  genes,	  respectively,	  
and	  the	  polymerase	  genes	  were	  not	  analyzed.	  	  Therefore,	  we	  did	  not	  evaluate	  
recombinant	  strains	  or	  genotypic	  variants.	  
	  
CONCLUSION	  
In	  summary,	  this	  hospital-­‐based	  case-­‐control	  study	  documents	  the	  substantial	  
contribution	  of	  caliciviruses—particularly	  norovirus	  and	  sapovirus—to	  medically-­‐
attended	  pediatric	  gastroenteritis	  in	  a	  developing	  setting	  following	  Rotarix™	  vaccine	  
implementation.	  	  These	  findings,	  in	  addition	  to	  studies	  of	  diarrhea	  in	  the	  community	  
setting,	  strongly	  suggest	  the	  need	  for	  a	  triple	  vaccine	  targeting	  rotavirus,	  norovirus,	  





In	  conclusion,	  these	  studies	  helps	  extend	  the	  knowledge	  of	  the	  complex	  
epidemiology	  of	  norovirus	  infection	  and	  disease	  in	  two	  developing	  country	  
populations,	  young	  children	  and	  the	  Peruvian	  military.	  	  The	  hospital-­‐based	  case-­‐
control	  study	  of	  young	  children	  with	  and	  without	  diarrhea	  demonstrates	  the	  
substantial	  contribution	  of	  caliciviruses—particularly	  norovirus	  and	  sapovirus—to	  
medically-­‐attended	  pediatric	  gastroenteritis	  in	  a	  developing	  setting	  following	  
Rotarix™	  vaccine	  implementation.	  	  These	  findings	  srongly	  suggest	  the	  need	  for	  a	  
triple	  vaccine	  targeting	  rotavirus,	  norovirus,	  and	  sapovirus	  to	  prevent	  diarrhea,	  
malnutrition,	  and	  hospitalization	  among	  young	  children	  in	  developing	  settings.	  	  In	  
military	  adults	  stationed	  in	  the	  Peruvian	  Amazon	  Basin,	  norovirus	  also	  contributed	  
significantly	  to	  disease.	  	  In	  this	  setting,	  norovirus	  is	  second	  only	  to	  Shigella	  as	  the	  
leading	  cause	  of	  gastroenteritis.	  Analysis	  of	  the	  cost-­‐effectiveness	  of	  norovirus	  
vaccine	  implementation	  in	  Peruvian	  military	  service	  members	  demonstrates	  that	  
military	  gastroenteritis	  vaccine	  acquisition	  strategies	  should	  focus	  on	  vaccines	  
against	  Shigella	  and	  norovirus.	  	  	  
	  
In	  summary,	  molecular	  diagnostics	  have	  drastically	  improved	  our	  understanding	  of	  
gastrointestinal	  pathogens.	  	  Investigations	  of	  the	  etiology	  of	  gastroenteritis	  in	  
developing	  settings	  suggest	  that	  the	  disease	  burden	  of	  caliciviruses,	  specifically	  
norovirus	  and	  sapovirus,	  are	  high,	  making	  it	  a	  leading	  cause	  of	  diarrhea-­‐associated	  
morbidity	  and	  mortality	  worldwide.	  	  In	  high-­‐income	  countries,	  norovirus	  infection	  
frequently	  affects	  children,	  the	  elderly,	  immunocompromised	  individuals,	  health	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care	  workers,	  food	  handlers,	  travelers,	  and	  the	  military.	  	  In	  developing	  settings,	  
young	  children	  experience	  the	  highest	  incidence	  of	  norovirus-­‐associated	  disease;	  
however,	  it	  also	  affects	  adults	  in	  special	  populations,	  such	  as	  military	  personnel,	  in	  
these	  settings.	  	  Immunity	  to	  norovirus	  is	  variant-­‐	  or	  genotype-­‐specific,	  and	  has	  
limited	  duration.	  	  .	  	  	  
	  
Vaccines	  against	  norovirus	  are	  rapidly	  approaching	  the	  market.	  	  These	  vaccines	  are	  
based	  on	  virus	  like	  particle	  or	  P	  particle	  subunit	  production	  in	  expression	  systems.	  	  
One	  of	  the	  vaccine	  implementation	  challenges	  is	  that	  many	  distinct	  population	  
groups	  are	  affected.	  	  However,	  disease	  burden	  data,	  particularly	  in	  developing	  
setting	  populations,	  are	  scarce.	  	  Further,	  remaining	  methodological	  controversies	  
over	  norovirus	  disease	  estimation	  remain.	  	  Due	  to	  the	  high	  sensitivity	  of	  molecular	  
detection	  methods,	  norovirus	  is	  frequently	  identified	  in	  stools	  from	  healthy	  
individuals,	  making	  the	  interpretation	  of	  disease	  attribution	  complex.	  	  	  Critical	  
knowledge	  gaps	  also	  include	  understanding	  natural	  immunity	  to	  norovirus	  and	  
correlates	  of	  protection,	  the	  roles	  of	  specific	  age	  groups	  in	  norovirus	  transmission,	  
and	  the	  implications	  of	  human	  genetic	  susceptibility	  to	  norovirus	  for	  population	  
health,	  viral	  evolution,	  and	  vaccines.	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  Adjusteda	  
	  
Risk	  Factor	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  OR	   95%	  CI	   p-­‐value	   OR	   95%	  CI	   	  	  p-­‐value	  
	   	  
NV	  GII	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2.4	  	  	  	   (1.1–5.6)	   	  0.03	   3.4	   (1.3–8.7)	   	  	  	  	  0.012	  
Shigella	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  6.5	   (3.0–14.2)	   	  <0.001	   6.7	   (3.0–14.8)	  	   	  <0.001	  
Enterotoxigenic	  Escherichia	  coli	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  8.5	   (1.9–37.6)	   0.005	   9.1	  	   (2.0–41.2)	  	   	  0.004	  
Trichuris	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.5	   (0.3–0.8)	   0.006	   0.4	   (0.3–0.8)	   	  	  	  	  0.005	   	  
	   	  
Abbreviations:	  	  NV	  =	  norovirus,	  GII	  =	  Norovirus	  genogroup	  II,	  OR	  =	  Odds	  Ratio,	  CI	  =	  
Confidence	  Interval	  	  
a	  Adjusted	  model	  includes	  Norovirus	  GII,	  Shigella,	  Enterotoxigenic	  Escherichia	  coli,	  
and	  Trichuris 	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Table	  3.	  Norovirus	  Genotypes/Variants	  Detected	  in	  Stool	  Samples	  from	  Peruvian	  
Military	  Personnel	  with	  and	  without	  Gastroenteritis	  in	  the	  Amazon	  Basin	  	  
Genotype/Variant	  (N=25)	   Total	  





Genogroup	  I	   	   	   	  
GI.1	   1	  (4)	   1	  (4)	   0	  (0)	  
GI.3	   1	  (4)	   1	  (4)	   0	  (0)	  
GI.4	   7	  (28)	   4	  (16)	   3	  (12)	  
GI.5	   1	  (4)	   0	  (0)	   1	  (4)	  
GI.7	   1	  (4)	   1	  (4)	   0	  (0)	  
Genogroup	  II	   	   	   	  
GII.4/2006b	  Den	  Haag	   6	  (24)	   6	  (24)	   0	  (0)	  
GII.5	   1	  (4)	   1	  (4)	   0	  (0)	  
GII.6	   1	  (4)	   1	  (4)	   0	  (0)	  
GII.14	   1	  (4)	   1	  (4)	   0	  (0)	  
GII.15	   1	  (4)	   1	  (4)	   0	  (0)	  
GII.16	   2	  (8)	   2	  (8)	   0	  (0)	  
GII.17	   2	  (8)	   2	  (8)	   0	  (0)	  
Total	   25	  (100)	   21	  (84)	   4	  (16)	  
Abbreviations:	  	  GI	  =	  norovirus	  genogroup	  I,	  GII	  =	  norovirus	  genogroup	  II	  
a	  	  In	  addition	  to	  those	  reported	  in	  the	  table,	  16	  noroviruses	  were	  untypeable	  because	  
no	  amplicon	  was	  produced	  on	  conventional	  PCR	  (0	  norovirus	  GI	  and	  7	  GII)	  or	  






Table	  6.	  Parameter	  Estimates	  Used	  for	  the	  Pathogen-­‐Specific	  Gastroenteritis	  
Vaccine	  Cost	  Effectiveness	  Analysis	  Applied	  to	  the	  Peruvian	  Military	  Population	  	  
Estimate	   Reference	  
Deployment	  parameters	  
	  
Yearly	  deployment	  size	   120,660	   (“Global	  Fire	  Power”	  2016)	  	  
	  
Deployment	  duration	  in	  months	   3.5	   Unpublished	  data	  (Guerra	  R)	  
	  
Time-­‐horizon	  (years)	   1	   (Tallant	  et	  al.	  2014b)	  	  
	  
Discount	  rate	   0.00%	   (Tallant	  et	  al.	  2014b)	  
Gastroenteritis	  
	  
Monthly	  incidence	  (as	  percent)	   6.5%	   (Ballard,	  Reaves,	  et	  al.	  2015a)	  	  
	  
Vaccine	  covered	  pathogen	  prevalence	   14.1%	   (Ballard,	  Reaves,	  et	  al.	  2015a)	  	  
Vaccine	  acquisition	  program	  
	  
Vaccine	  coverage	   75%	   (Riddle	  et	  al.	  2008)	  	  
	  
Vaccine	  efficacy	   80%	   (Riddle	  and	  Tribble	  2008)	  	  
	  
[P]	  of	  adverse	  event	  needing	  treatment	   0.0125%	   (Riddle	  et	  al.	  2008)	  	  
	  
Cost	  of	  vaccine	  administration	   $0.50	   (A.	  D.	  Clark	  et	  al.	  2009)	  
	  
Cost	  per	  dose	  of	  vaccine	   $7.50	   (A.	  D.	  Clark	  et	  al.	  2009)	  
	  
Number	  of	  doses	  needed	   2	   (Mirelman	  et	  al.	  2015a;	  Tallant	  et	  al.	  2014b)	  	  
	  
Cost	  per	  adverse	  event	  treated	   $104	   Unpublished	  data	  (Guerra	  R)	  
Current	  management	  approach	  
	  
[P]	  seeking	  medical	  treatment	  for	  
illness	   76.90%	   (Ballard,	  Reaves,	  et	  al.	  2015a)	  	  
	  
[P]	  not	  seeking	  medical	  treatment	   23.10%	   (Ballard,	  Reaves,	  et	  al.	  2015a)	  	  
	  
[P]	  medical	  evacuation	  (MEDEVAC)	   0.0329%	   (Tallant	  et	  al.	  2014b)	  	  
Treatment	  type	  provided	  
	  
[P]	  ambulatory	  (outpatient)	   63.50%	   (Ballard,	  Reaves,	  et	  al.	  2015a)	  
	  
[P]	  confinement	  to	  bed	  rest	   32.00%	   (Ballard,	  Reaves,	  et	  al.	  2015a)	  	  
	  
[P]	  hospitalization	   4.50%	   (Ballard,	  Reaves,	  et	  al.	  2015a)	  	  
Cost	  of	  treatment	  type	  provided	  ($)	  
	  
Medical	  evacuation	  (note	  cost	  is	  per	  
hour)	   S/.10,007.76	   Unpublished	  data	  (Guerra	  R)	  
	  
Hospitalization	  (deployed)	   S/.473.36	   Unpublished	  data	  (Guerra	  R)	  
	  
Sick	  in	  quarters/Confinement	  to	  bed	  
rest	   S/.79.84	   Conservative	  estimate	  based	  on	  (Tallant	  et	  al.	  2014b)	  	  
	  
Ambulatory	   S/.79.84	   Unpublished	  data	  (Guerra	  R)	  
	  
Annual	  investment	  on	  treatment	  trials	   n/a	   n/a	  
Abbreviations:	  [P]	  =	  probability	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Table	  7.	  Baseline	  Estimates	  of	  Total	  Costs,	  Effectiveness	  Measures,	  and	  Cost-­‐
Effectiveness	  Ratios	  for	  Pathogen-­‐Specific	  Analysis	  of	  Vaccines	  Against	  
Campylobacter,	  ETEC,	  Shigella,	  and	  Norovirus	  in	  a	  Peruvian	  Military	  Population	  in	  
the	  Amazon	  Basin	  	  
Pathogen	  
Campylobacte
r	   ETEC	   Shigella	   Norovirus	  
Annual	  vaccine-­‐preventable	  illness	  events	  	   137	   2,223	   5,902	   3,870	  
Annual	  cost	  of	  immunizing	  target	  population	  	   $1,447,920	   $1,447,920	   $1,447,920	   $1,447,920	  
	  
Annual	  number	  of	  gastroenteritis	  events	  (pre-­‐licensure:	  post-­‐licensure)	  
Outpatient	   66:10	   1,082:162	   2,872:430	   1,884:282	  
Sick	  in	  quarters/Confinement	  to	  bed	  rest	   34:5	   550:82	   1459:219	   957:144	  
Hospitalization	   5:1	   77:12	   205:31	   135:20	  
Aeromedical	  evacuation	   0:0	   1:0	   2:0	   1:0	  
	  
Total	  cost	  of	  care	  for	  vaccine	  acquisition	  strategy	   $543	   $8,802	   $23,364	   $15,322	  
Total	  cost	  of	  care	  for	  current	  management	   $3,622	   $58,681	   $155,758	   $102,148	  
Annualized	  cost	  of	  care	  averted	  by	  vaccine	  acquisition	  
strategy	   $3,079	   $49,879	   $132,394	   $86,826	  
	  
Total	  duty	  days	  lost	  vaccine	  acquisition	  strategy	   23	   240	   940	   368	  
Total	  duty	  days	  lost	  current	  management	   116	   1,201	   4,669	   1,839	  
Annualized	  duty	  days	  lost	  averted	  due	  to	  vaccine	  
acquisition	  strategy	   93	   961	   3,759	   1,471	  
	  
Cost	  effectiveness	  ratio	  (US$/duty	  days	  lost	  averted)	   $15,598	   $1,456	   $350	   $926	  
Cost	  effectiveness	  ratio	  (US$/diarrhea	  day	  averted)	   $2,418	   $246	   $60	   $229	  
Abbreviations:	  ETEC	  =	  Enterotoxigenic	  Escherichia	  coli	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Table	  8.	  	  Population	  Characteristics	  and	  Pathogens	  Detected	  in	  Stool	  Samples	  from	  
Children	  Younger	  than	  Five	  Years	  of	  Age	  with	  and	  without	  Medically-­‐attended	  
Gastroenteritis	  	  in	  Peru	  	  
	   CASES,	  n=932	   CONTROLS,	  n=856	   P-­‐
value	  Population	  characteristics,	  n=1,788	  
Male,	  number	  (%)	   528	   56.7%	   434	   50.7%	   0.01	  
Age	  (mos),	  mean	  (SD)	   21.5	   13.0	   24.9	   16.0	   <0.01	  
	  	  	  	  	  0-­‐5	  mos,	  number	  (%)	   19	   2.0%	   24	   2.8%	   0.11	  
	  	  	  	  	  6-­‐11	  mos,	  number	  (%)	   191	   20.5%	   155	   18.1%	   <0.01	  
	  	  	  	  	  12-­‐23	  mos,	  number	  (%)	   410	   44.0%	   260	   30.4%	   <0.01	  
	  	  	  	  	  24-­‐35	  mos,	  number	  (%)	   171	   18.3%	   146	   17.1%	   0.26	  
	  	  	  	  	  36-­‐47	  mos,	  number	  (%)	   79	   8.5%	   152	   17.8%	   <0.01	  
	  	  	  	  	  48-­‐59	  mos,	  number	  (%)	   62	   6.7%	   119	   13.9%	   <0.01	  
Socieoeconomic	  score	  ,	  median	  (range)	   39	   (4-­‐59)	   32	   (6-­‐54)	   <0.01	  
Improved	  sanitation	  (WHO	  definition),	  number	  (%)	   872	   93.6%	   339	   39.6%	   <0.01	  
Improved	  water	  source	  (WHO	  definition),	  number	  (%)	   839	   90.2%	   353	   41.2%	   <0.01	  
Hematocrit,	  mean	  (SD)	   35.0	   2.8	   35.5	   2.6	   <0.01	  
Blood	  group	   	  	   	  	   	  	   	  	   	  	  
	  	  	  	  	  O,	  number	  (%)	   578	   81.4%	   673	   82.1%	   0.39	  
	  	  	  	  	  A,	  number	  (%)	   92	   13.0%	   106	   12.9%	   0.52	  
	  	  	  	  	  B,	  number	  (%)	   37	   5.2%	   37	   4.5%	   0.3	  
	  	  	  	  	  AB,	  number	  (%)	   3	   0.4%	   4	   0.5%	   0.58	  
Rhesus	  factor	  positive,	  number	  (%)	   704	   99.2%	   817	   99.6%	   0.32	  
Weght	  for	  age	  Z-­‐score,	  mean	  (SD)	   0.11	   1.28	   0.53	   1.23	   <0.01	  
Weight	  for	  length/height	  Z-­‐score,	  mean	  (SD)	   0.18	   1.74	   0.57	   1.42	   <0.01	  
Length/height	  for	  age	  Z-­‐score,	  mean	  (SD)	   0.06	   2.28	   0.31	   1.81	   0.02	  
BMI	  for	  age	  Z-­‐score,	  mean	  (SD)	   0.15	   1.92	   0.52	   1.55	   <0.01	  
Rotavirus	  dose	  1,	  number	  (%)	   876	   96.6%	   676	   92.0%	   <0.01	  
Rotavirus	  dose	  2,	  number	  (%)	   833	   91.8%	   628	   85.4%	   <0.01	  
Season	   	  	   	  	   	  	   	  	   	  	  
	  	  	  	  	  Summer	  (December	  -­‐	  February),	  number	  (%)	   247	   26.5%	   154	   18.0%	   <0.01	  
	  	  	  	  	  Fall	  (March	  -­‐	  May),	  number	  (%)	   298	   32.0%	   255	   29.8%	   <0.01	  
	  	  	  	  	  Winter	  (June	  -­‐	  August),	  number	  (%)	   172	   18.5%	   212	   24.8%	   0.11	  
	  	  	  	  	  Spring	  (September	  -­‐	  November),	  number	  (%)	   215	   23.1%	   235	   27.5%	   <0.01	  
	  	   	  	   	  	   	  	   	  	   	  	  
Microbes,	  number	  (%)	   677	   72.6%	   378	   44.2%	   <0.01	  
Viruses	   528	   56.7%	   178	   20.8%	   <0.01	  
	  	  	  	  	  Aichivirus	   1	   0.2%	   1	   0.3%	   1	  
	  	  	  	  	  Astrovirus	   48	   5.2%	   23	   2.7%	   <0.01	  
	  	  	  	  	  Norovirus	   337	   36.2%	   106	   12.4%	   <0.01	  
	  	  	  	  	  	  	  	  	  	  GI	   29	   3.1%	   30	   3.5%	   0.69	  
	  	  	  	  	  	  	  	  	  	  GII	   312	   33.5%	   77	   9.0%	   <0.01	  
	  	  	  	  	  Rotavirus	   98	   10.5%	   29	   3.4%	   <0.01	  




Table	  9.	  Results	  of	  the	  Logistic	  Regression	  Analysis	  Demonstrating	  the	  Relationship	  
between	  the	  Presence	  of	  Specific	  Pathogens	  in	  Stool	  and	  Gastroenteritis	  Among	  
Children	  in	  Lima,	  Peru	  	  
	   	   	  
	  	  	  	  	  	  	  	  	  	  	  Crude	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Adjusteda	  
	  
Risk	  Factor	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  OR	   95%	  CI	   P-­‐value	   AOR	   95%	  CI	   	  	  P-­‐value	  
	   	  
Shigella	   9.1	   2.1-­‐39.0	   0.003	   9.1	   1.2-­‐43.0	   0.005	  
Norovirus	  GII	   5.1	   3.9-­‐6.7	   <0.001	   6.4	   4.4-­‐9.4	   <0.001	  
Rotavirus	   3.4	   2.2-­‐5.1	   <0.001	   6.0	   2.8-­‐12.6	   <0.001	  
Sapovirus	   3.0	   1.9-­‐4.8	   <0.001	   3.6	   2.0-­‐6.6	   <0.001	  
ETEC	  St+	   3.5	   1.6-­‐7.2	   0.001	   3.1	   1.2-­‐8.2	   0.021	  
Astrovirus	   2.0	   1.2-­‐3.3	   0.009	   2.2	   1.0-­‐4.4	   0.005	  
Parasite	  (Any)	   0.3	   0.2-­‐0.5	   <0.001	   0.3	   0.2-­‐0.5	   <0.001	  
	  	   	  
Abbreviations:	  GII	  =	  Norovirus	  genogroup	  II,	  OR	  =	  Odds	  Ratio,	  CI	  =	  Confidence	  
Interval,	  	  	  
a	  Adjusted	  model	  includes	  age,	  sex,	  socioeconomic	  status,	  Shigella,	  norovirus	  GII,	  
rotavirus,	  enterotoxigenic	  Escherichia	  coli	  (St+	  and	  Lt+/St+),	  sapovirus,	  astrovirus,	  




Table	  10.	  	  Clinical	  Features	  and	  Severity	  of	  Gastroenteritis	  by	  Pathogen	  in	  Children	  Younger	  than	  Five	  Years	  of	  Age	  in	  Peru	  
Clinical	  features	  (cases	  only)	   All	  cases,	  
n=932	  











Vesikari	  score,	  mean	  (SD)	   12.1	   2.3	   12.9	   2.3	   12.6	   2.3	   12.3	   2.3	   12.8	   2.2	   11.7	   2.3	   12.0	   2.0	  
	  	  	  	  	  Mild,	  number	  (%)	   231	   25%	   3	   14%	   52	   17%	   24	   24%	   6	   18%	   21	   26%	   12	   0.25	  
	  	  	  	  	  Severe,	  number	  (%)	   701	   75%	   18	   86%	   260	   83%	   74	   76%	   27	   82%	   60	   74%	   36	   0.75	  
Clark	  score,	  mean	  (SD)	   11.5	   2.2	   12.1	   2.5	   11.7	   2.3	   11.5	   1.8	   11.7	   2.4	   11.2	   2.2	   11.4	   2.1	  
	  	  	  	  	  Mild,	  number	  (%)	   84	   9%	   1	   5%	   26	   8%	   6	   6%	   4	   12%	   11	   14%	   4	   8%	  
	  	  	  	  	  Moderate,	  number	  (%)	   839	   90%	   20	   95%	   280	   90%	   92	   94%	   29	   88%	   70	   86%	   44	   92%	  
	  	  	  	  	  Severe,	  number	  (%)	   9	   1%	   0	   0	   6	   2%	   0	   0	   0	   0	   0	   0	   0	   0	  
Diarrhea	  reported,	  number	  (%)	   830	   89%	   21	   100%	   294	   94%	   92	   94%	   31	   94%	   76	   94%	   43	   90%	  
Duration	  of	  diarrhea	  among	  those	  with	  diarrhea	  	  
	  	  	  	  	  (days),	  mean	  (SD)	  
4.9	   2.9	   6.8	   1.2	   5.3	   2.9	   4.5	   1.7	   6.7	   3.7	   5	   2.5	   4.9	   2.4	  
Maximum	  daily	  number	  of	  diarrheal	  stools,	  mean	  	  
	  	  	  	  	  (SD)	  
4.7	   2.9	   6.0	   3.0	   5.0	   2.6	   4.4	   3.1	   4.7	   3	   4.5	   2.3	   4.3	   2.5	  
Number	  of	  children	  with	  vomiting	  (%)	   768	   82%	   15	   71%	   288	   92%	   86	   88%	   25	   76%	   69	   85%	   33	   69%	  
Duration	  of	  vomiting	  among	  those	  with	  vomiting	  	  
	  	  	  	  	  (days),	  mean	  (SD)	  
2.6	   1.7	   2.1	   4.7	   2.8	   1.7	   2.5	   1.4	   2.6	   1.8	   2.5	   1.3	   3.0	   2.1	  
Maximum	  number	  of	  vomiting	  episodes	  in	  one	  day,	  	  
	  	  	  	  	  mean	  (SD)	  
3.5	   3.1	   3.2	   3.4	   4.4	   3.3	   3.2	   3.2	   2.6	   2.6	   3.4	   2.8	   2.9	   3.0	  
Fever	  reported,	  number	  (%)	   511	   55%	   15	   71%	   176	   56%	   52	   100
%	  
20	   61%	   27	   33%	   26	   54%	  
Duration	  of	  fever	  among	  those	  with	  fever	  (days),	  	  
	  	  	  	  	  mean	  (SD)	  
2.2	   1.3	   1.7	   1	   2.3	   1.5	   2	   1.2	   2.2	   1.7	   2.4	   1.4	   2.0	   1.0	  
Behavioral	  symptoms	  irritable,	  number	  (%)	   162	   17%	   1	   5%	   59	   18%	   9	   9%	   12	   36%	   13	   16%	   13	   27%	  
Behavioral	  symptoms	  listless,	  number	  (%)	   551	   59%	   16	   76%	   172	   52%	   65	   66%	   12	   36%	   47	   58%	   23	   48%	  
Behavioral	  symptoms,	  seizure,	  number	  (%)	   0	   0%	   0	   0%	   0	   0%	   0	   0%	   0	   0%	   0	   0%	   0	   0%	  
Dehydration	  mild,	  number	  (%)	   499	   45%	   14	   67%	   172	   52%	   48	   49%	   22	   67%	   49	   60%	   25	   52%	  
Dehydration	  moderate	  to	  severe,	  number	  (%)	   2	   0%	   0	   0%	   0	   0%	   0	   0%	   0	   0%	   0	   0%	   0	   0%	  






48	   100%	  
Treatment	  given-­‐	  intravenous	  (parenteral)	  	  
	  	  	  	  	  rehydration,	  number	  (%)	  
1	   0%	   0	   0%	   0	   0%	   0	   0%	   0	   0%	   0	   0%	   0	   0%	  
Abbreviations:	  GII	  =	  Genogroup	  II;	  ETEC	  =	  Enterotoxigenic	  Escherichia	  coli;	  St+	  =	  Heat	  stabile	  toxin	  positive;	  Lt+/St+	  Heat	  labile	  and	  heat	  stabile	  toxin	  positive;	  n	  =	  Number;	  SD	  =	  Standard	  deviation	  
	  
	  74	  
VII.	  	  FIGURES	  
	  
Figure	  1.	  	  Map	  of	  Peru,	  Indicating	  the	  Peruvian	  Military	  Study	  Site	  of	  Iquitos	  in	  the	  
Peruvian	  Amazon	  Basin	  and	  Lima,	  the	  Capital	  City	  where	  the	  National	  Children’s	  
Hospital	  is	  Located	  
	  
Figure	  2.	  	  Flow	  Diagram	  of	  Peruvian	  Military	  Participant	  Enrollment	  and	  Selection	  
of	  Participants	  for	  the	  Nested	  Case-­‐Control	  Study	  
	  
Figure	  3.	  	  Economic	  model	  evaluating	  the	  cost-­‐effectiveness	  of	  vaccines	  against	  
specific	  gastroenteritis-­‐associated	  pathogens	  for	  a	  Peruvian	  military	  population,	  
taken	  from	  (Tallant	  et	  al.	  2014a)	  	  	  
	  
Figure	  4.	  	  One-­‐way	  Sensitivity	  Analyses	  for	  the	  Cost-­‐Effectiveness	  Analyses	  of	  
Vaccines	  Against	  (A)	  Campylobacter;	  (B)	  ETEC;	  (C)	  Shigella;	  and	  (D)	  Norovirus	  in	  the	  
Peruvian	  Military	  Population	  in	  the	  Amazon	  Basin	  
	  
Figure	  5.	  	  Rotavirus	  prevalence	  over	  study	  period	  demonstrating	  the	  relationship	  
between	  rotavirus	  seasonality	  (red	  line)	  and	  rotavirus	  genotype	  G12P[8]	  prevalence	  
(green	  line),	  Peru,	  2013-­‐15	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Figure	  1.	  	  Map	  of	  Peru,	  Indicating	  the	  Peruvian	  Military	  Study	  Site	  of	  Iquitos	  in	  the	  
Peruvian	  Amazon	  Basin	  and	  Lima,	  the	  Capital	  City	  where	  the	  National	  Children’s	  
Hospital	  is	  Located	  	  










Figure	  3.	  	  Economic	  model	  evaluating	  the	  cost-­‐effectiveness	  of	  vaccines	  against	  
specific	  gastroenteritis-­‐associated	  pathogens	  for	  a	  Peruvian	  military	  population,	  
taken	  from	  (Tallant	  et	  al.	  2014a)	  	  	  
	  





Figure	  5.	  	  Rotavirus	  prevalence	  over	  study	  period	  demonstrating	  the	  relationship	  
between	  rotavirus	  seasonality	  (red	  line)	  and	  rotavirus	  genotype	  G12P[8]	  prevalence	  
(green	  line),	  Peru,	  2013-­‐15	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  Center	  for	  Security	  Studies	  Fellow,	  2009	  
	  
Board	  Certifications	  and	  Academic	  Certificates	   	  
• Diplomate,	  American	  Board	  of	  Preventive	  Medicine,	  Aerospace	  Medicine,	  2014	  
• Diplomate,	  American	  Board	  of	  Preventive	  Medicine,	  General	  Preventive	  Medicine,	  2013	  
• ASTMH	  Certificate	  of	  Knowledge	  in	  Clinical	  Tropical	  Medicine	  and	  Travelers’	  Health,	  2012	  
• Tropical	  Medicine	  Diploma	  Course,	  Johns	  Hopkins,	  2012	  
• Conflict	  Analysis	  Certificate,	  U.S.	  Institute	  of	  Peace,	  2010	  
• Negotiation	  and	  Conflict	  Management,	  US	  Institute	  of	  Peace,	  2010	  
• Interfaith	  Conflict	  Resolution	  Certificate,	  US	  Institute	  of	  Peace,	  2010	  
• Strategy	  and	  War	  Course	  Certificate,	  Naval	  War	  College,	  2010	  
• Health	  Finance	  and	  Management	  Certificate,	  Johns	  Hopkins,	  2010	  
• Naval	  Trauma	  Training	  Center	  Advanced	  Course,	  Los	  Angeles	  County	  +	  USC,	  2010	  
• Health	  Emergencies	  in	  Large	  Populations	  Certificate,	  COE-­‐DMHA,	  2009	  
• Combined	  Humanitarian	  Assistance	  Response	  Training,	  COE-­‐DMHA,	  2008	  
• Military	  Tropical	  Medicine	  Diploma	  Course,	  USUHS,	  2007	  
• Military	  Medical	  Humanitarian	  Assistance	  Certificate,	  USUHS,	  2007	  
	   	   	   	  
Faculty	  Appointments	  and	  Teaching	  Experience	  
• Adjunct	  Assistant	  Professor,	  Department	  of	  Preventive	  Medicine	  &	  Biometrics,	  Uniformed	  Services	  
University	  of	  the	  Health	  Sciences,	  “Military	  Tropical	  Medicine,”	  2012-­‐present,	  Field	  Course	  
Director	  	  
• Johns	  Hopkins	  PH.221.639.81	  “Refugee	  Health	  Care,”	  2011-­‐12,	  Lead	  Teaching	  Assistant	  (TA)	  
• Johns	  Hopkins	  PH.221.613.01	  “Introduction	  to	  Humanitarian	  Emergencies,”	  2011-­‐12,	  Lead	  TA	  
• Johns	  Hopkins	  PH.550.609.19	  “Problem	  Solving	  in	  Public	  Health,”	  2012,	  2013,	  Lead	  TA	  
• Johns	  Hopkins	  PH.221.661.01	  “Project	  Development	  in	  Developing	  Countries,”	  2011-­‐12,	  Lead	  
TA	  
• Johns	  Hopkins	  PH.180.670.01	  	  “Introduction	  to	  Public	  Health,”	  2011-­‐13,	  Lead	  TA	  
• Johns	  Hopkins	  PH.180.670.01	  “Health	  Emergencies	  in	  Large	  Populations,”	  2012,	  Lead	  TA	  
	  
Elected/Appointed	  Positions	  
• President,	  American	  College	  of	  Preventive	  Medicine	  (ACPM),	  Resident	  Physician	  Section,	  2013-­‐14	  
• Vice	  President	  for	  Policy	  and	  Education,	  ACPM	  Resident	  Physician	  Section,	  2012-­‐13	  
• Board	  of	  Directors,	  Uniformed	  Services	  Academy	  of	  Preventive	  Medicine,	  2012-­‐15	  
• Board	  of	  Governors,	  Ex-­‐officio,	  American	  Journal	  of	  Preventive	  Medicine,	  2012-­‐13	  
• Young	  Professional	  Board	  Member,	  American	  Red	  Cross	  of	  Central	  Maryland,	  2011-­‐13	  
• Health	  Committee	  Member,	  American	  Red	  Cross,	  Hawaii	  State	  Chapter,	  2008-­‐11	  
• Pandemic	  Preparedness	  Officer,	  Marine	  Corps	  Base	  Hawaii,	  2009-­‐10	  
• Education	  and	  Training;	  Aviation	  Safety	  Committee	  Aerospace	  Medical	  Association,	  2008-­‐09;	  
2012-­‐14	  
	  
Humanitarian	  Assistance/Disaster	  Relief	  Field	  Work	  
• Medical	  Coordinator,	  Ebola	  Rapid	  Response	  Initiative,	  International	  Medical	  Corps,	  2014-­‐15	  
• Human	  Rights	  Clinic	  Physician,	  HealthRight	  International,	  2011-­‐13	  
• Disaster	  Action	  Team,	  Young	  Professionals	  Board,	  American	  Red	  Cross	  of	  Central	  Maryland,	  2011-­‐
13	  
• Emergency	  Doctor,	  Disaster	  Action	  Team,	  certified	  in	  Disaster	  Assessment,	  Health	  Services,	  Mass	  
Care,	  Shelter,	  and	  Logistics	  Volunteer,	  American	  Red	  Cross,	  Hawaii	  State	  Chapter,	  2008-­‐11	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• Navy	  Medical	  Liaison,	  Dhi	  Qar	  Provincial	  Reconstruction	  Team,	  Iraq,	  2008-­‐09	  
• Supervising	  Flight	  Surgeon,	  Combined	  Joint	  Task	  Force-­‐Horn	  of	  Africa,	  for	  three	  Medical	  Civic	  
Action	  Immunization/Primary	  Care	  Project	  Missions	  along	  the	  Djiboutian-­‐Somali-­‐Ethiopian	  
borders,	  2008	  
• Military	  Medical	  Relief	  Worker	  for	  8.0	  earthquake	  in	  Pisco,	  Peru,	  2007	  
	  
Research	  &	  Service	  Awards	  
• Ashton	  Graybiel	  Award	  for	  impactful	  aviation	  research	  (2015)—Society	  of	  U.S.	  Naval	  Flight	  
Surgeons	  
• TIME	  Magazine	  Person	  of	  the	  Year	  (2014)—Ebola	  Fighters	  
• Elsevier	  Clinical	  Research	  Award	  (2013)	  –	  American	  Society	  of	  Tropical	  Medicine	  and	  Hygiene	  
• American	  Society	  of	  Tropical	  Medicine	  and	  Hygiene	  Travel	  Award	  (2013)	  
• Young	  Investigator	  Award	  Finalist	  (2013)	  –	  Aerospace	  Medical	  Association,	  top	  7%	  of	  206	  
abstracts	  
• Aerospace	  Medicine	  Students	  and	  Residents	  Organization	  (2013)	  –	  AsMA	  Conference	  Travel	  Award	  
• John	  Paul	  Stapp	  Prize	  in	  aviation	  research	  (2012)	  –Johns	  Hopkins	  Center	  for	  Injury	  Research	  and	  
Policy	  	  
	  
Selected	  Military	  Decorations/Awards	  
• Richard	  E.	  Luehrs	  Operational	  Flight	  Surgeon	  of	  the	  Year,	  Navy-­‐Marine	  Corps	  (2010)	  
• Chief	  of	  Naval	  Operations	  Safety	  Award	  (2010)	  
• Overseas	  Service	  Ribbon	  (2015)	  
• Navy	  “Blue	  M”	  Outstanding	  Fleet	  Medical	  Readiness	  Awards	  (2008	  and	  2009)	  
• Combat	  Patrol	  and	  Reconnaissance	  Wing	  TWO	  Flight	  Surgeon	  of	  the	  Year	  (2008	  and	  2009)	  
• US	  Navy	  Surgeon	  General’s	  “Blue	  H”	  Health	  Promotions	  Awards	  (2008	  and	  2009)	  
• U.S.	  Naval	  Flight	  Surgeon	  Qualification	  (2008)	  
• Fleet	  Marine	  Force	  Qualified	  Officer	  (2011)	  
• Individual	  Strike/Flight	  Air	  Medals	  (2009	  and	  2011)	  
• Afghan	  Campaign	  Medal	  (2010)	  
• North	  Atlantic	  Treaty	  Organization	  Medal	  (2010)	  
• Outstanding	  Volunteer	  Service	  Medal	  (2010)	  
• Navy	  and	  Marine	  Corps	  Achievement	  Medals	  (2008	  and	  2010)	  
• Iraq	  Campaign	  Medals	  –	  Iraqi	  Surge	  (2008)	  and	  Iraqi	  Sovereignty	  (2009)	  
• Sea	  Service	  Medals	  (2009	  and	  2010)	  
• Advanced	  Rotary	  Wing	  (Bell	  TH-­‐57	  Jet	  Ranger)	  Aviation,	  US	  Navy	  (2008)	  
• Primary	  Fixed	  Wing	  (Beechcraft	  T-­‐34	  Turbo	  Mentor)	  Aviation,	  US	  Navy	  (2008)	  	  
• Aviation	  Preflight	  Indoctrination,	  US	  Navy	  (2007)	  
• Humanitarian	  Service	  Medal	  (2007),	  Letter	  of	  Commendation,	  US	  Ambassador	  to	  Peru	  (2007)	  
	  
Military	  Extracurricular	  Leadership	  Activities	  
• Mentor	  for	  “Academy	  Women,”	  a	  non-­‐profit	  global	  leadership	  organization	  for	  current	  and	  former	  
military	  officers,	  cadets,	  midshipmen,	  candidates,	  and	  allies	  to	  support	  women	  leadership	  (2008-­‐
present)	  
• Interviewer,	  Health	  Professions	  Scholarship	  Program	  (2011-­‐present)	  
• Field	  Clinical	  Preceptor,	  Military	  Tropical	  Medicine	  Civic	  Action	  Project,	  Peru	  (2012-­‐present)	  
• Navy	  Delegate,	  Hawaii	  Governor’s	  International	  Leadership	  Conference	  (2008,	  2009)	  
	  
Academic	  Honors	  
• Delta	  Omega,	  Alpha	  Chapter,	  Johns	  Hopkins	  (2010)	  
• Phi	  Beta	  Kappa,	  Agnes	  Scott	  College	  (2002)	  
• Agnes	  Scott	  College	  Outstanding	  Young	  Alumnus	  (2009)	  
• Agnes	  Scott	  College	  Mortar	  Board	  (2002)	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Ongoing	  Research	  Support	  
P0376-­‐14-­‐N6	   	   	   	   Ballard	  (PI)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  10/01/14-­‐
10/01/16	  
Department	  of	  Defense	  Global	  Emerging	  Infections	  Surveillance	  System	  Program	   	  	  	  	  	  	  	  	  	  	  	  	  	  $182,000	  
Role	  of	  loggers	  in	  malaria	  re-­‐introduction/	  re-­‐emergence	  in	  low	  endemic	  areas	  in	  the	  Peruvian	  
Amazon	  
	  
20160390130	  	   	   	   Ballard	  (PI)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  10/01/15-­‐
10/01/16	  
Department	  of	  Defense	  Global	  Emerging	  Infections	  Surveillance	  System	  Program	   	  	  	  	  	  	  	  	  	  	  	  	  	  $415,000	  
Malaria	  surveillance	  sustainment	  
	  
Completed	  Research	  Support	  
P0067-­‐13-­‐N6	   	   	   	   Ballard	  (PI)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  10/01/13-­‐
10/01/15	  
Department	  of	  Defense	  Global	  Emerging	  Infections	  Surveillance	  System	  Program	   	  	  	  	  	  	  	  	  	  	  	  	  	  $199,800	  
In	  vivo	  efficacy	  of	  artemisinin	  combination	  therapy	  in	  Peru	  to	  determine	  parasite	  clearance	  rates	  in	  
uncomplicated	  P.	  falciparum	  malaria	  
	  
Procter	  &	  Gamble	  Fellowship	   	   Ballard	  (PI)	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  08/01/14-­‐
05/31/15	  
Johns	  Hopkins	  Bloomberg	  School	  of	  Public	  Health	  Endowed	  Research	  Award	   	   	  	  	  	  	  	  	  	  	  	  
$17,780.00	  
Scholarship	  awarded	  to	  students	  committed	  to	  advancing	  the	  health	  and	  well-­‐being	  of	  women	  and	  
children	  through	  the	  provision	  of	  clean	  water	  and	  improved	  nutrition.	  
	  
U.S.	  Fulbright	  Research	  Award	  –	  Peru	   Ballard	  (PI)	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  08/01/14-­‐
04/30/15	  
United	  States	  Department	  of	  State	   	   	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  $9,000.00	  
The	  goal	  of	  this	  award	  is	  to	  increase	  mutual	  understanding	  between	  people	  of	  the	  United	  States	  
and	  the	  people	  of	  Peru	  through	  intellectual	  exchange	  of	  technology	  and	  epidemiological	  research	  
skills.	  
	  
R.	  Bradley	  Sack	  Family	  Scholarship	  	   Ballard	  (PI)	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  06/01/14-­‐
05/31/15	  
Johns	  Hopkins	  Bloomberg	  School	  of	  Public	  Health	  Endowed	  Research	  Award	   	   	  	  	  	  	  	  	  	  	  	  	  	  
$4,350.00	  
This	  fund	  supports	  outstanding	  doctoral	  students	  studying	  infectious	  diseases	  in	  the	  developing	  
world.	  
	  
Early	  Career	  Award	  	   	   	   Ballard	  (PI)	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  02/02/14-­‐
01/31/15	  
Thrasher	  Research	  Fund	   	   	   	   	   	   	   	   	  	  	  	  	  	  	  	  	  	  
$25,000.00	  
The	  goal	  of	  this	  award	  is	  to	  encourage	  the	  development	  of	  young	  investigators	  in	  pediatric	  medical	  
research.	  	  It	  supports	  the	  evaluation	  of	  medically-­‐attended	  norovirus-­‐associated	  diarrhea	  in	  Peru.	  
	  
Centennial	  Travel	  Award	   	   Ballard	  (PI)	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  09/15/13-­‐
09/14/14	  
American	  Society	  of	  Tropical	  Medicine	  and	  Hygiene	   	   	   	   	  	  	  	  	  	  	  	  	  	  $25,000.00	  
The	  goal	  of	  this	  award	  is	  to	  provide	  short-­‐term	  research	  experience	  in	  the	  tropics.	  	  It	  funds	  
technical	  personnel	  and	  equipment	  for	  the	  norovirus	  hospital	  study.	  
	  
Graduate	  Research	  Award	  Program	   Ballard	  (PI)	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  08/01/13-­‐
07/31/14	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National	  Academies	  of	  Science,	  Transportation	  Research	  Board	   	   	   	  	  	  	  	  	  	  	  	  	  $10,000.00	  
The	  goal	  of	  this	  fund	  is	  to	  encourage	  applied	  research	  on	  airport	  and	  related	  aviation	  system	  issues	  
and	  to	  foster	  the	  next	  generation	  of	  aviation	  community	  leaders.	  
	  
David	  and	  Elinor	  Bodian	  Foundation	  	   Ballard	  (PI)	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  09/01/13-­‐
05/16/14	  
Johns	  Hopkins	  Bloomberg	  School	  of	  Public	  Health	  Endowed	  Research	  Award	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